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Abstract
Glioma is a brain tumor that arises from glial cells or glial progenitor cells, and represents 80% of
malignant brain tumor incidence in the United States. Glioblastoma multiforme (GBM) is the most
aggressive primary brain tumor malignancy with fewer than 8% of patients with GBM surviving for 3 years.
Over the past 10 years, despite improvement in diagnosis and therapies for cancer, the survival rate for
high-grade glioma patients remains unchanged. The main focus of this dissertation is to investigate two
therapeutic agents that are related to increase tumor resistance or increase secondary tumor incidence,
which might play a role in poor prognosis and outcome for glioma. There are several studies, which show
that corticosteroid treatment increases tumor resistance to chemo- and radiotherapy. Corticosteroids are
mainstay drugs for managing peritumoral edema. Therefore, we investigated the effect of corticosteroids
in a PDGF driven glioma mouse model. We found that corticosteroid treatment decreases tumor cell
proliferation without inducing cell death as shown by a significant decrease in PCNA and Ki67 but not in
cleaved caspase-3 staining. Decreased tumor cell growth could compromise the responsiveness of tumor
cells to chemotherapy and/or radio-therapy, because cancer therapeutics often target rapidly growing
cells. In addition, we found that corticosteroids decrease tumorassociated microglial cells proliferation.
Furthermore, in vitro and in vivo studies revealed a shift in microglial cells to less pro-tumor phenotype as
evidenced by decreasing MMP9 and IL-1ra expression. However, we did not find an association between
the decrease in tumor proliferation and the shift in microglia phenotype. In addition, the use of thiopurine
drugs in leukemia treatment was associated with the development of secondary cancers including
glioma. Therefore, we investigated the cytotoxic effects of thiopurine drugs in primary astroglial cultures.
Thiopurine drugs are commonly used to treat cancer, autoimmune disorders, and transplantation.
However, thiopurines and their metabolites can be inactivated by the thiopurine methyltransferase (TPMT)
enzyme. We found that a low TPMT phenotype predicted significantly higher sensitivity to the cytotoxic
action of thiopurines than did a high TPMT phenotype. Thiopurines induced significantly more cell death
and DNA damage in primary astrocytes and human glioma cells with low TPMT versus high TPMT. It is
possible that the DNA damage caused by low TPMT function can ultimately contribute to transformative
events over time. Finally, we assessed the anticancer activity of 2 classes of novel small molecules;
tetrahydroisoquinoline (THIQ) and chromenes. These molecules were screened in vitro to find the most
potent anticancer derivatives that exhibited the least toxicity on normal stromal cells. EDL-360 (5-10 µM)
and SP-6-27 (IC50 = 7-21 nM) were the most potent analogs of THIQ and chromene in glioma cells,
respectively, and low cytotoxic action was observed in normal astrocytes. Furthermore, theses
compounds induced a partial regression in glioma tumor engraftment.
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ABSTRACT
Glioma is a brain tumor that arises from glial cells or glial progenitor cells, and
represents 80% of malignant brain tumor incidence in the United States. Glioblastoma
multiforme (GBM) is the most aggressive primary brain tumor malignancy with fewer
than 8% of patients with GBM surviving for 3 years. Over the past 10 years, despite
improvement in diagnosis and therapies for cancer, the survival rate for high-grade
glioma patients remains unchanged. The main focus of this dissertation is to investigate
two therapeutic agents that are related to increase tumor resistance or increase secondary
tumor incidence, which might play a role in poor prognosis and outcome for glioma.
There are several studies, which show that corticosteroid treatment increases tumor
resistance to chemo- and radiotherapy. Corticosteroids are mainstay drugs for managing
peritumoral edema. Therefore, we investigated the effect of corticosteroids in a PDGF
driven glioma mouse model. We found that corticosteroid treatment decreases tumor cell
proliferation without inducing cell death as shown by a significant decrease in PCNA and
Ki67 but not in cleaved caspase-3 staining. Decreased tumor cell growth could
compromise the responsiveness of tumor cells to chemotherapy and/or radio-therapy,
because cancer therapeutics often target rapidly growing cells. In addition, we found that
corticosteroids decrease tumor-associated microglial cells proliferation. Furthermore, in
vitro and in vivo studies revealed a shift in microglial cells to less pro-tumor phenotype as
evidenced by decreasing MMP9 and IL-1ra expression. However, we did not find an
association between the decrease in tumor proliferation and the shift in microglia
phenotype. In addition, the use of thiopurine drugs in leukemia treatment was associated
with the development of secondary cancers including glioma. Therefore, we investigated
the cytotoxic effects of thiopurine drugs in primary astroglial cultures. Thiopurine drugs
are commonly used to treat cancer, autoimmune disorders, and transplantation. However,
thiopurines and their metabolites can be inactivated by the thiopurine methyltransferase
(TPMT) enzyme. We found that a low TPMT phenotype predicted significantly higher
sensitivity to the cytotoxic action of thiopurines than did a high TPMT phenotype.
Thiopurines induced significantly more cell death and DNA damage in primary
astrocytes and human glioma cells with low TPMT versus high TPMT. It is possible that
the DNA damage caused by low TPMT function can ultimately contribute to
transformative events over time. Finally, we assessed the anticancer activity of 2 classes
of novel small molecules; tetrahydroisoquinoline (THIQ) and chromenes. These
molecules were screened in vitro to find the most potent anticancer derivatives that
exhibited the least toxicity on normal stromal cells. EDL-360 (5-10 μM) and SP-6-27
(IC50 = 7-21 nM) were the most potent analogs of THIQ and chromene in glioma cells,
respectively, and low cytotoxic action was observed in normal astrocytes. Furthermore,
theses compounds induced a partial regression in glioma tumor engraftment.
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CHAPTER 1.

INTRODUCTION

Glioma arises from glial cells or glial progenitor cells, and is the most frequent
type of brain tumor [1]. Glial cells, which include astrocytes, oligodendrocytes and
ependymal cells, support and maintain normal brain homeostasis. Each of these glial cell
types can give rise to a distinctive type of cancer. Glioblastoma multiforme (GBM),
however, is the most aggressive primary brain tumor malignancy [1,2]. Despite the fact
that GBM is infrequent, it is clinically significant because more than 60% of the patients
die within 1 year from diagnosis [2]. One of the major concerns is glioma resistance to
chemotherapy and radiotherapy, which enables tumor cells to repopulate, and thus
causing relapse in 50% of the patients. Recurring tumors are usually more aggressive and
resistant to therapy [3]. In the past 10 years, the survival rate remains substantially low
for glioma patients. The basic hypothesis to be examined in this thesis is that therapy
related resistance and toxicity play a role in the poor prognosis and outcome in glioma.
The objectives of this study are:
1- To investigate the effects of corticosteroids (anti-edema) in glioma.
2- To investigate thiopurine (anti-leukemia) induced toxicity in astrocytes with
different TPMT phenotypes.
3- To characterize novel small molecules that exhibit anti-glioma activity.
Glioma Epidemiology
The global incidence of malignant brain tumors is estimated to be approximately
3 in 100,000 per year, with a higher rate in the developed countries compared to the
developing countries [4,5]. According to the Central Brain Tumor Registry of the United
States (CBTRUS) report, an incidence of 109,695 malignant brain tumors were reported
between 2005-2009 [2]. Gliomas represent 29% of primary brain tumors and 80% of
malignant brain tumors. Three-year relative survival rate of the low-grade diffuse
astrocytoma is 55%, while it is less than 8% of GBM patients. Of note, the mortality rate
increases with age. For example, a 5 year relative survival for GBM patients in the fourth
decade of their life is approximately 17%, but for the patients in the seventh decade of
their life is 1.6% [2]. In addition, being a white male increases the risk for developing
malignant glioma. However, females are at higher risk for non-malignant brain tumors
[5].
Clinical Presentation
At clinical presentation, the most frequent symptoms for newly diagnosed and
relapsed glioma patients are headache, behavioral changes, hemiparesis, seizures, nausea
and vomiting [6]. Typically, the headache is worse in the morning but gradually
alleviates during the day. Nevertheless, brain tumor patients often suffer from changes in
personality and cognitive abilities [3]. One of the major concerns is the development of
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neurological symptoms and irreversible neurological damage due to the size of these
tumors and their critical location in the brain [3]. In addition to these neurological
defects, GBM patients usually suffer from cerebral edema, which is characterized by an
increased brain volume due to leakage of the plasma into brain parenchyma (5).
Peritumoral edema is considered to be a significant cause of death because it leads to
increased intracranial pressure (ICP) [7]. Corticosteroids are often employed to alleviate
these neurological symptoms [8], but have been corticosteroid treatment has been
associated with various adverse effects that interfere with the quality of life of the patient.
The adverse effects include behavioral changes, insomnia, myopathy, hyperglycemia,
weight gain, peptic ulcer [9]. Moreover, withdrawal of steroid therapy is also associated
with severe side effects including steroid withdrawal syndrome (i.e. headache and
lethargy) and adrenal insufficiency due to a lack of the production of endogenous
corticosteroids [9,10]. The effect of corticosteroids on glioma disease will be discussed in
chapter 2.
Diagnosis
Brain tumor diagnosis starts with non-invasive anatomic imaging techniques such
as computerized tomography (CT). X-ray CT scans provide volume imaging by a
simultaneous movement of the X-ray source and the film from one position to another.
Consequently, tumor location and the associated structure can be identified. The problem
with the CT scans, however, is that the images are quite blurry [6,11]. Alternatively,
magnetic resonance imaging (MRI) provides a more sensitive detection of small size
tumors, location and other abnormal tissue structure. Moreover, it is considered to be safe
since it utilizes radio-frequency waves (i.e. non-radioactive). However, it is a more
expensive approach than CT scans [12]. Proton Magnetic Resonance Spectroscopic
Imaging (1H-MRSI) is another advanced imaging tool that provides more accurate
information about the location as well as the cellular and metabolic activity of the tumor
[13,14]. On T2-weighted MRI, low grade astrocytomas appear as hyperintense (bright)
area with defined borders [6]. Owing to the infiltrative nature of high grade gliomas, they
exhibit irregular contrast enhancement and involve both hemispheres [6]. Although MRI
imaging is a valuable diagnostic tool, the final tumor identification and grading is not
confirmed until histopathological analysis of a patients’ biopsy is performed [3].
Histopathological and Molecular Classification
Histopathological Classification
According to the World Health Organization (WHO), gliomas can be
histologically classified into several categories based on their morphological resemblance
to glial cells. Within each category, the tumors are further graded based on malignancy.
The grades are designated by numbers range from “I”, for the least malignant tumors, to
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“IV”, for most the malignant tumors [15]. For example, astroglial tumors closely
resemble astrocytes whereas oligodendroglial tumors resemble oligodendrocytes.
Low-grade piloctic astrocytomas typically arise in the hypothalamic region and
usually they are not accompanied with cerebral edema [6,15]. However, high-grade
astrocytomas, including anaplastic astrocytoma and GBM (Figure 1-1), arise in the
cerebral cortex. GBMs are highly heterogeneous and complex in nature, and their
incidence peaks in the fifth and the sixth decade of life [1,6]. Necrotic regions,
hemorrhage, pleomorphic nuclei and vascular proliferation are characteristic of GBM. In
addition, GBM highly infiltrates normal tissue forming the secondary structures of
Scherer, in which tumor cells surround blood vessels, neurons and subpial zone in the
cereberal cortex [16].
Molecular Classification
Histologically similar tumors can vary significantly on a molecular basis. The
Cancer Genome Atlas (TCGA) dataset has been used to classify GBM into 4 molecular
subclasses: classical, mesenchymal, proneural, and neural [17,18]. The frequently altered
oncogenes and tumor suppressor genes in glioma are summarized in Figure 1-2 [19]. The
Epidermal growth factor receptor (EGFR) overexpression is frequently altered in the
"Classical" subtype of GBM. Moreover, combined deletion of INK4a/ARF and EGFR
amplification are observed in 94% of this subtype. Neurofibromin 1 (NF1) is a tumor
suppressor gene that is mutated in 18% of GBM cases and 53% of "Mesenchymal"
molecular subtype of glioma [18,20]. However, proneural subclass of GBM is
characterized by frequent amplification in platelet derived growth factor receptor
(PDGFR) (11%) and point mutations in isocitrate dehydrogenase 1 (IDH1) (30%). In
addition, TP53 and PTEN are altered in 54% and 16% of proneural subclass cases [18].
Finally, neural subclass is characterized by neural markers expression; NEFL, GABRA1,
SYT1, and SLC12A5. EGFR is also frequently amplified in this subclass but to a lesser
extent compared to the classical subtype.
Glioma Treatment
Ionizing Radiation
The heterogeneous nature of GBM plays a prominent role in therapeutic
resistance [1]. The treatment of brain tumors involves both local and systemic therapeutic
approaches. Typically tumor resection is employed to remove the majority of the tumor
[1,3]. However, complete tumor resection is very challenging due to the diffuse
infiltrative nature of these tumors into normal brain parenchyma [21]. As a result, these
tumors can repopulate and increase in size significantly after surgery [3]. Cranial
irradiation often follows surgical resection. The radiotherapy can alleviate the
neurological symptoms and seizures in glioma patients [3]. However, radiotherapy is not
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Figure 1-1.

Histological and molecular classification of gliomas.

According to the WHO gliomas can be histologically classified into several groups
depending on the glial cell of origin. Recent studies further identified 4 molecular
subclasses of GBM.
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Figure 1-2.

Molecular pathways frequently altered in glioma.

Binding of EGF/PDGF growth factors to the EGFR/PDGFR tyrosine kinase receptor
leads to the activation of RAS/RAF and RAS/PI3K survival pathways. Tumor suppressor
genes NF1 and PTEN inhibit the activity of RAS and PI3K oncogenes, respectively.
Ink4a and ARF tumor suppressor genes are frequently mutated in glioma and their loss
leads to silencing RB and p53 respectively. Adapted with permission from Patil SA,
Hosni-Ahmed A, Jones TS, Patil R, Pfeffer LM, et al. (2013) Novel approaches to glioma
drug design and drug screening. Expert Opin Drug Discov 8: 1135-1151.
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recommended for elderly patients (> 70 years) because the side effects of irradiation are
usually more severe in the elderly. Typically, the radiotherapy regimen is 54-60 Gy given
in 30 fractions during 6 weeks of treatment [3]. However, it is not recommended to delay
radiotherapy for GBM patients from the time of presentation as it might decrease the
overall patient survival rate [22].
Chemotherapy
Systemic chemotherapy is another treatment option for GBM patients. In 1999,
the Food and Drug Administration (FDA) approved Temozolomide (TMZ; Temodar®)
for treating refractory anaplastic astrocytoma, and in 2005 TMZ was approved for GBM
treatment. Concurrent treatment of 75 mg of TMZ /m2/day and irradiation followed by
~150 mg of TMZ /m2/day prolonged the median survival rate to 14.6 months versus 12.1
months for radiotherapy alone [23,24]. This adjuvant TMZ therapy was given 5
days/week for 1 year (28 day cycle) [23]. Of note, the methylation status of
O6-methylguanine-DNA methyltransferase (MGMT) promoters is a good predictor of the
sensitivity to TMZ therapy. In particular, unmethylated active MGMT enzyme
compromises TMZ genotoxicity by removing the alkyl group from the DNA [25].
Therefore, glioma patients with unmethylated MGMT promoter are more resistant to
TMZ compared to patients harboring methylated MGMT. Finally, Bevacizumab
(Avastin®) is another chemotherapeutic agent that was recently approved for recurrent
GBM [24].
Corticosteroids in Managing Peritumoral Edema
Despite the fact that corticosteroids are not directly employed as anti-neoplastic
drugs, they are essential component in managing peritumoral edema. Glucocorticoids are
stress hormones that control a wide variety of biological processes such as inflammation,
metabolism and behavior [26]. Dexamethasone (Dex), a synthetic corticosteroid, is the
most favored corticosteroid drug used by clinicians, whereas the second preferred drug is
methylprednisolone. This owes to the long biological half-life of Dex and the minimal
mineralocorticoid effect [27]. The dose employed is quite variable depending on patient
symptoms. However, the rule of thumb is to use the lowest dose for the shortest period of
time to avoid the undesirable side effects of corticosteroids. Additionally, gradual
tapering of Dex is critical to avoid corticosteroid withdrawal syndrome. Corticosteroid
treatment suppresses the function of the hypothalamic-pituitary-adrenal axis and gradual
withdrawal allows the recovery of hypothalamic-pituitary-adrenal axis function [9].
Dex may be used before, during or after radiotherapy, or before or after surgery.
At the time of clinical presentation, the starting dose of Dex is 16 mg/day for one week.
However, if the patient is unconscious, 40 mg of Dex is given intravenously [8,9]. After 7
days, the dose is adjusted based on patient’s symptoms and the extent of tumor resection.
In case the patient’s symptoms are improving and the tumor has been surgically removed,
the dose is reduced 50% every 4 days. However, if the symptoms do not improve, the
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dose can be increased up to 100 mg of Dex daily [8]. In addition, radiotherapy treatment
can cause a slight increase in brain volume, which might require Dex treatment.
Corticosteroids
Mechanism of Action
Corticosteroids achieve their anti-inflammatory effect by acting as a
trans-activators or trans-repressors of gene transcription. They are lipophilic substances
that can pass through the plasma cell membrane by simple diffusion. Once inside the cell,
they bind to glucocorticoid receptors (GR) in the cytoplasm [28]. The hormone-receptor
homodimer complex releases the 90 kDa heat-shock protein that allows the complex to
translocate into the nucleus [29]. Binding of the complex to the glucocorticoid responsive
elements (GRE) on the DNA drives the expression of anti-inflammatory cytokines such
as interleukin-10 (IL-10) and interleukin 1 receptor antagonist (IL-1ra) [30]. However,
the glucocorticoid-receptor complex can act as a trans-repressor as well by suppressing
the expression of pro-inflammatory cytokines. This activity is achieved by interfering
with and inhibiting transcription factors, such as NF-κB and activating protein 1 (AP-1),
which drives the expression of pro-inflammatory cytokines [31,32]. Recently,
glucocorticoids have also been shown to play a role in chromatin remodeling and hence
RNA transcription [33]. GR can bind to and inhibit the function of CREB binding protein
(CBP). CBP causes histone acetylation that allows DNA unwinding and hence makes
DNA more accessible for transcription machinery. Additionally, GR recruits histone
deacetylase-2 (HDAC2), therefore allowing the compaction of DNA and suppression of
gene expression [33,34].
Possible Effects of Corticosteroids on Glioma
Dex is intensively used in the clinic for alleviating peritumoral edema. However,
the exact mechanism of how Dex alleviates cerebral edema is unknown. Furthermore, the
effect of dexamethasone on tumor cells is controversial. For instance, some studies
suggested that it has an anti-proliferative effect in vivo [35]. While other studies have
shown that dexamethasone stimulates cell growth at low concentrations and inhibits cell
growth at high concentration [36]. This is particularly important because cancer
therapeutics often target rapidly growing cells. Therefore, Dex might compromise the
responsiveness of tumor cells to DNA damaging agents such as chemo and/or
radio-therapies by slowing down tumor cell replication. Indeed, the use of corticosteroid
has shown to increase tumor’s radioresistance, however, this effect seems to be cell type
dependent [37]. Perhaps the upregulation of steroid receptors following ionizing radiation
therapy is the mechanism responsible for Dex-induced radioresistance [38]. Such
findings highlight the desperate need to understand the specific effect of Dex on tumor
cells especially for patients undergoing concomitant chemotherapy or radiotherapy
concurrently with corticosteroids. In our studies, we investigated the effect of Dex on
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glioma cell proliferation and death using a genetically engineered mouse model of
glioma. However, Dex is not the only drug being associated with severe adverse effect
and toxicity. For example the development of secondary tumors in patients has been
associated with thiopurine drug treatment.
Thiopurine Drugs
Thiopurine Metabolism
Thiopurine drugs (i.e. thioguanine, mercaptopurine, and azathioprine) are
commonly used in the treatment of cancer, autoimmune disorders, and transplantation.
These agents are pro-drugs that require intracellular conversion to the cytotoxic
thioguanine nucleotide (TGN) metabolites by a series of enzymatic reactions to exert
their effects [39]. The primary mechanism of thiopurine cytotoxicity is believed to be
through the incorporation of TGNs into DNA (DNA-TG) followed by methylation of the
DNA-TG bases and subsequent processing by the mismatch repair system [40].
Additionally, inhibition of de novo purine synthesis by methylthioinosine monophosphate
(meTIMP) is believed to play some role in how thiopurine drugs work; however
thioguanine bypasses the conversion to meTIMP. Alternatively, thiopurines and their
metabolites can be inactivated by the thiopurine methyltransferase (TPMT) enzyme.
Thiopurine Methyltransferase
TPMT is a cytoplasmic enzyme that catalyzes the S-methylation of aromatic and
heterocyclic compounds using S-adenosyl-L-methionine as a methyl donor. However, the
endogenous substrate for TPMT has not yet been identified [41]. Indeed, TPMT has been
studied extensively because of its critical role in the biotransformation of thiopurine
agents and because of deactivating polymorphisms that can result in low protein activity
[42,43]. The genetic polymorphism in TPMT results in a trimodal population frequency
distribution in TPMT protein activity. Approximately 90% of the population have
homozygous wild-type TPMT and have high TPMT protein activity; ~10% are
heterozygous with intermediate protein activity; and less than 1% are homozygous
mutant for TPMT and have practically no measurable protein activity. TPMT protein
levels are inversely correlated with the cytotoxic TGN metabolites. Hence, low TPMT
protein can lead to high levels of intracellular TGNs and life threatening side effects
when normal thiopurine doses are administered.
The consequence of low TPMT protein activity is evident in leukemia patient
populations who receive thiopurines as part of their antileukemic therapy. When these
patients have a low TPMT phenotype and receive normal doses of thiopurines they are at
a high risk of life-threatening myelosuppression and secondary cancers [44-46].
Interestingly, one study found that patients who had a low TPMT phenotype and were
treated with normal doses of thiopurines concurrently with cranial irradiation as part of
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their antileukemic therapy were at a higher risk of developing brain cancer as compared
to patients with normal TPMT [47,48]. However, little is known about TPMT function in
brain cells. It is plausible that low TPMT function can result in high levels of DNA
damage without killing the cells and this might lead to cellular transformation.
Thiopurines and Incidence of Secondary Brain Tumors
Thiopurine therapy has been associated with cancer development in organ
transplantation and autoimmune disorder patients (Table 1-1); however, the importance
of TPMT status is unclear. Unfortunately, with the exception of leukemia patients, most
patient populations are not evaluated for their TPMT status prior to initiating thiopurine
therapy. Since TPMT deficiency is rare across populations, it is difficult to assess the
importance of TPMT status to thiopurine therapy-associated cancer risk. Here, we
provide a review of the literature of thiopurine drug therapy-related cancers followed by
an evaluation of TPMT phenotypes in astroglial cells.
Various types of cancer have been observed in patients who have received
long-term thiopurine therapy (Table 1-1). A study conducted by Kandiel et al. found that
inflammatory bowel disease patients treated with AZA have a four-fold increased risk of
lymphoma [49]. Additionally, there have been several reports suggesting an increased
risk of malignancy in renal transplant patients who receive azathioprine, which include
cancers of the skin and brain as well as lymphomas and carcinomas [50-52]. The
incidence of cutaneous squamous cell carcinoma (SCC) in patients undergoing organ
transplantation is 100-fold greater than the normal population [53]. The interaction
between UVA radiation and DNA-TGN causes DNA single and double strand breaks
possibly due to ROS generation. This in part can explain the high risk of skin cancer in
organ transplant patients [54].
Thioguanine and mercaptopurine have been used for childhood acute
lymphoblastic leukemia (ALL) treatment for more than 50 years [55,56]. Several studies
have reported secondary neoplasms in children treated for ALL including brain cancers,
lymphomas, carcinomas and sarcomas [48,57-59]. In a protocol conducted at St. Jude
Children's Research Hospital, almost half of the patients having a low TPMT phenotype
and who were treated with thiopurines concurrently with cranial irradiation developed
brain tumors as a late-complication of their anti-leukemic therapy [47]. This raises the
question of whether TPMT can protect important brain cell populations (i.e. astrocytes)
from genotoxic events induced by thiopurines. We hypothesize that TPMT deficiency can
lead to greater DNA damage and cytotoxicity in astroglial cell populations.
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Table 1-1.
Thiopurines
AZA

Incidences of secondary neoplasm after thiopurine therapy.
Primary
disease
Kidney
transplant

Therapy related
cancer
Nodular malignant
melanoma
Brain lymphoma
Glioblastoma

Number of
patients affected
1 patient in the
case study
25 patients in the
case study
3 out of 5 patients
in the case study
2 patients in the
case study
3 patients out of
5867
2 patients out of
212
1 patient in the
case study
1 patients out of 1

Reference
[51]
[52]
[60]

∏

Myasthenia
gravis
Inflammatory
bowel disease

MP

Inflammatory
bowel disease
ALL

CNS lymphoma
Lymphoproliferative
disorder Ω
Non-Hodgkin’s
lymphoma
Hepatocellular
carcinoma
Hodgkin’s
lymphoma
Hodgkin’s
lymphoma
Lymphoma
Brain tumor
MDS
PTLD
Oral carcinoma
Oral carcinoma
Thyroid carcinoma
PNET
Intracranial
neoplasms ¶

1 patient out of
5867
5 patients out of 5
7 out of 188
patients†
8 out of 1225
patients
1 out of 1225
patients
1 out of 1225
patients
1 out of 1225
patients
1 out of 1225
patients
1 out of 1225
patients
1 out of 2 patients
in the case study æ

[61]
[62]
[63]
[64]
[65]
[62]
[65]
[47]
[66]
[66]
[66]
[66]
[66]
[66]
[67]

Abbreviations:
ALL, acute lymphoblastic leukemia; AML, actute myloid leukemia; AZA, azathiopurine;
MP, mercaptopurine; MDS, Myelodysplasic syndrome PNET, primitive neuroectodermal
tumor in central nervous system; PTLD, post-transplantation lymphoproliferative disease
∏ These three patients received azathiopurine
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Table 1-1.

Continued.

Ω Lymphoproliferative disorder (LD) includes Anaplastic large cell LD, immunoblastic
B-cell lymphoma and B follicular lymphoma
† The incidence of secondary brain tumors in TPMT deficient patients is 42.9% while in
TPMT proficient patients is 8.3%
¶ Neuroectodermal tumor with astrocytic and neuroblastic nature.
æ This patient received mercaptopurine

11

CHAPTER 2.

THE EFFECTS OF CORTICOSTEROIDS ON GLIOMA AND
MICROGLIAL CELLS
Introduction

Glioblastoma Multiforme
GBM is one of the most devastating and aggressive types of brain cancer.
According to the CBTRUS report, an incidence of 109,695 malignant brain tumors was
reported between 2005-2009 [2,68]. Despite the therapeutic advancement, the estimated
overall survival is 3 years for approximately only 7% of the patients [2]. The typical
treatment strategy starts with tumor resection to remove the bulk of the tumor. However,
complete tumor resection is very challenging due to the diffuse infiltration nature of the
tumor into normal brain parenchyma [21]. In addition, tumor recurrence is inevitable for
glioma patients, partially because of failure to remove all tumor cells. Surgical resection
of the tumor is then followed by aggressive radio-therapy and chemo-therapy
(Temozolomide) [69-71].
Tumor Associated Edema
High-grade gliomas such as GBM are usually associated with cerebral edema,
which is characterized by an increase in the brain volume due to leakage of the plasma
into brain parenchyma (5). Peritumoral edema is considered to be a significant cause of
death because it leads to increased intracranial pressure (ICP) [7]. At clinical
presentation, headache, nausea, vomiting and impaired eye movement are the typical
symptoms, which substantially impair the quality of life of brain tumor patients [6,9].
Since the introduction of Dex, a synthetic glucocorticoid, to medical practice in 1962,
there has been outstanding improvement in patients’ survival [72]. To date, Dex is the
cornerstone for the management of cerebral edema with no superior alternative therapy
[8,9]. However, Dex has been associated with numerous side effects especially with the
long-term use of high doses, including behavioral changes, insomnia, myopathy,
hyperglycemia, weight gain and peptic ulcer. Moreover, withdrawal of steroid therapy is
also associated with severe side effects including steroid withdrawal syndrome (i.e.
headache and lethargy) and adrenal insufficiency due to the lack of production of
endogenous corticosteroids [9,10]. Therefore, there is an urgent need to discover equal or
superior alternatives with fewer side effects. Although how Dex induces its anti-edema
effect is largely unknown, it is thought that Dex might achieve its effect by acting on
microglial cells [73]. Indeed, microglial secretion of key inflammatory mediators (i.e.
matrix metalloproteinases and prostaglandin) that contributes to blood brain barrier
(BBB) damage [74,75].
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The Effect of Dex on Glioma Cells
Despite the intensive use of Dex for alleviating peritumoral edema, varying
effects of Dex on glioma cells in vitro have been found in different cell systems. Grasso
et al. demonstrated that 1 μM Dex had an anti-proliferative effect on rat glioma cultures
[76]. Similarly, ependymoblastoma-bearing mice treated with 40 mg/kg of Dex had lower
tumor size and showed a reduction in thymidine incorporation into DNA [35]. However,
the effect of steroids appears to be highly dependent on their concentration. For example,
Dex increases the proliferative capacity of human astrocytoma cultures at low
concentration, while it is cytotoxic at high concentrations (> 50 μM) [36,77]. For the
most part, these studies used non-physiological concentrations of Dex and/or the
treatment schedule did not recapitulate the treatment regimen in brain tumor patients. In
the current study Dex treatment regimen was carefully chosen to represent its use in the
clinical settings. To be able to mimic the in vivo effect and to have reliable meaningful
data, our in vitro cell cultures were treated with physiological concentrations of Dex.
The Effect of Dex on Microglial Cells
To add another layer of complexity there is a dynamic interaction between
microglia and tumor cells in the tumor microenvironment. In particular, tumor cells have
the capability to silence microglia’s immunological responses and shift their polarization
to M2-like phenotype [78]. In return M2-like microglia secrete factors that could support
tumor proliferation and invasion [79,80]. However, the effect of Dex on this symbiotic
relationship has not been determined. Since GBM patients have a poor prognosis and
very low survival rate, it becomes particularly important to identify the effect of Dex on
both glioma cells and stromal cells. Whether Dex influences tumor microglial cell
polarization or its consequence on the tumor progression is not precisely identified. It is
also unknown whether Dex is interfering with the efficacy of radiotherapy and
chemotherapy. Therefore, the aim of our study is to determine the effect of Dex on
glioma cell proliferation as well as the effect of Dex on microglial cell number and
phenotype.
To our knowledge, this is the first study that utilizes a clinically related glioma
mouse model to study the effects of Dex on tumor cells and tumor associated microglial
cells. In this model, mouse gliomas recapitulate the histopathological features of human
glioma, such as pseudopalisading necrosis, diffuse infiltration and microvascular
proliferation [81]. Therefore, the results from this study will be pivotal since it captures
several important features of the human disease. The Replication Competent ALV Splice
acceptor (RCAS)/ tva system was used to induce PDGF expression in nestin-expressing
cells. RCAS is a viral vector derived from the avian leukosis virus (ALV). Because tva
receptor is required for viral entry, the mice have been genetically engineered to express
the tva receptor in nestin expressing cells (Ntva). After PDGF expression in Ink4a/Arf-/mice, gliomas develop in all the mice within 6 weeks post viral injection [82].
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Materials and Methods
Generation of PDGF Induced Glioma Mouse Model
For theses studies, we employed a PDGF-induced glioma mouse model that was
generated in Dr. Eric Holland’s laboratory (Fred Hutchinson Cancer Research Center,
Seattle), in which the RCAS/tva system to drive the expression of PDGF in nestin
expressing cells (Ntva). First, the RCAS/PDGF viral vector (a generous gift from Dr.
Holland) was used to infect and overexpress PDGF in chicken fibroblast DF-1 cells
(DF-1/PDGF). Mock transfection (DF-1/GFP) was used to monitor infection efficiency
with a Nikon Eclipse TE300 fluorescent microscope. Plasmid-FuGENE mixture (1:6)
was used to transfect DF-1 cells for 48 hr. Subsequently, the cells were passaged and
monitored with a fluorescent microscope to determine the transfection efficiency. The
cells were maintained in DMEM media (Cellgro, Hemdon, VA) supplemented with 10%
FBS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin. PDGF viral
vector producing cells in the log phase (60-80%) was trypsinized and washed once with
PBS. After counting, cells were re-suspended in PBS at 100,000 cells/μl and placed on
ice immediately. Four to six week old Ink4a/Arf-/-/Ntva+ mice (a generous gift from Dr.
Holland) were deeply anesthetized with a ketamine/xylene mixture. Using a stereotactic
frame, 1 μl of cells were intracranially injected into the right frontal cortex. Starting from
the 4th week post-injection the mice were weighed daily and monitored for any sign of
sickness or neurological symptoms. Mice with symptoms, or those losing weight were
placed randomly in the study (Figure 2-1). For in vivo studies, the mice were treated for
3 days with DEX at 10 mg/kg body weight, which is expected to result in a Dex
concentration in brain tissue of ~ 1 μM [83,84]. In order to mimic in vivo conditions, the
primary cultures were treated with physiologically relevant doses (i.e. 0.1, 1 and 10 μM)
of Dex.
Primary Glioma Cultures
Glioma-bearing mice were sacrificed by transcardiac perfusion using ice-cold
PBS. The brain was removed and placed immediately in ice-cold PBS, subsequently the
tumor was carefully dissected with surgical tweezers, and single cell suspensions
prepared using papain dissociation system. First, the dissected tumor tissue was incubated
with papain solution (0.94 mg/ml papain, 0.18 mg/ml EDTA, 0.18 mg/ml N-Cystein and
0.1 mg/ml DNase in EBSS; Worthington Biochemical Corp. Lakewood, NJ) for 15 min
at 37°C. Then, ovomucoid solution (0.7 mg/ml ovomucoid, 0.014 mg/ml DNase in
neuro-basal media) was added to inactivate the enzymatic digestion by papain. After
centrifugation at 1200 rpm for 10 min, the cells were washed using neuro-basal media.
Subsequently, the cells were re-suspended in DMEM media (Cellgro, Hemdon, VA)
supplemented with 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml
streptomycin.
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Figure 2-1.

A cartoon representation of the experimental design.

RCAS/PDGF vector was used to infect DF-1 chicken fibroblast cells. Virus producing
cells were then intracranially injected into Ntva+; Ink4a/Arf-/-. When mice displayed
neurological symptoms or had lost weight they were treated with 0 or 10 mg/kg Dex for 3
days. Tumor samples from control and treated mice were used for IHC and Q RT-PCR
experiments. For in vitro testing, primary glioma cultures were generated from control
tumor-bearing mice using papain dissociation system and subjected to MTT and cell
cycle proliferation assays.
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Immunohistochemistry
Mice were anesthetized and perfused transcardially with saline followed by 10%
formalin. Brain samples were then post-fixed in neutral buffered 10% formalin solution
(Sigma-Aldrich, St. Louis, MO) for 24 to 72 hr. After fixation, tissue samples were
blocked with and paraffin embedded for sectioning (4 μM thick). Following re-hydrating,
the slides were microwaved for 10 min in citrate buffer (pH = 6.0) for antigen retrieval.
Then the slides were incubated with 3% hydrogen peroxide solution for 3 min at room
temperature to neutralize endogenous peroxidases. After permeabilization in 0.3% Triton
X-100 in PBS (PBST), the sections were blocked in 2% BSA, 5% normal goat serum,
0.1% Triton X-100 in PBS for 1 hr at room temperature. Primary antibodies were
incubated overnight at 4°C at a dilution of 1:500 (Iba-1; Wako Chemicals Inc. Richmond,
VA), 1:300 (Cleaved caspase-3; Cell Signaling Technology, Beverly, MA), 1:200 (Ki67;
Vector Laboratories, Burlingame, CA) and 1:2000 (PCNA; Dako, Carpinteria, CA). After
rinsing the slides 3 times in 0.1% PBST, the slides were incubated with biotinylated goat
anti-rabbit secondary antibody (Vector laboratories, Burlingame, CA) for Iba-1, cleaved
caspase-3, and Ki67. MOM kit (Vector Laboratories, Burlingame, CA) was used for
PCNA staining. The slides were then incubated with ABC solution (Vectastain ABC
Elite kit; Vector Laboratories, Burlingame, CA) for 30 min, washed 3 times in water and
then incubated with DAB solution (Vector Laboratories, Burlingame, CA) until the
brown color developed. After counterstaining the nucleus with hematoxlin
(Richard-Allan Scientific, Kalamazoo, MI), the slides were dehydrated and mounted with
permount mounting media (Fisher Scientific Co., Fair Lawn, NJ). Finally, the slides were
scanned with Aperio Spectrum system and analyzed using ImageScope v11.1.2.760
(Aperio, Vista, CA). The whole tumor regions were selected based on H&E staining and
positive pixels and negative pixels (unstained nuclei) were counted. Percent positivity
was calculated based on Equation 2-1;
% Positivity = (positive pixels *100) /total pixels

(Eq. 2-1)

To quantify of areas of necrosis, paraffin embedded tumor sections were stained
with hematoxylin and eosin (H&E). Subsequently, the slides were scanned using
Spectrum system from Aperio and analyzed using ImageScop v11.1.2.760 (Aperio Vista,
CA). The tumor region and regions of necrosis were selected and the necrotic index was
calculated according to Equation 2-2 [85];
Necrotic index = (Areas of necrosis (μm2)*100)/Total area of tumor section (μm2)
(Eq. 2-2)
Immunofluorescence
Immunofluorescence double staining was performed on re-hydrated brain
sections. The slides microwaved for 10 min in citrate buffer pH 6.0 for antigen retrieval.
After permeabilization in 0.3% triton X-100 in PBS (PBST), the sections were blocked in
2% BSA, 5% normal donkey serum, 0.1% triton X-100 in PBS for 1 hr at room
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temperature. Anti-Iba-1 (1:250; Wako Chemicals Inc. Richmond, VA) or anti-olig2
(1:100; Millipore Co., Bedford, MA) primary antibodies were incubated overnight at 4
°C. After rinsing the slides 3 times in 0.1% PBST, the slides were incubated with Alexa
Fluor 555 conjugated goat anti-rabbit secondary antibody (1:500; Molecular Probes Life
Technologies Inc., Grand Island, NY). The slides were then washed 3 times in 0.1%
PBST and incubated with the anti-PCNA primary antibody (1:100; Dako, Carpinteria,
CA) for 1 hr. Subsequently, the sections were incubated for 1 h at room temperature with
Alexa Fluor 448 conjugated goat anti-mouse secondary antibody (1:500; Molecular
Probes Life Technologies Inc., Grand Island, NY). Finally, vectashield mounting media
(Vector Laboratories, Burlingame, CA) containing DAPI was used to stain nuclei. Slides
were then visualized on a LSM Zeiss 700 microscope, 20X objective, 2X zoom. At least
200 cells were analyzed per slide for Olig2+ staining and 50 cells for Iba-1+ staining.
The percentage of Iba-1 positive cells were quantified in primary glioma cultures
by immunocytochemical analysis. Cells were fixed with 4% PFA/PBS for 10 min, and
permeabilized with 0.5% Triton X-100/PBS for 5 min. Cells were then washed with PBS
and blocked with 3% BSA/PBS for 1 h. Cells were immunostained with anti-Iba-1
(1:250; Wako Chemicals Inc. Richmond, VA) for 1 h. Subsequently, cells were washed
with PBS and incubated for 1 h with in Alexa Fluor 555 conjugated goat anti-rabbit
secondary antibody (1:500; Molecular Probes Life Technologies Inc., Grand Island, NY).
Finally, vectashield mounting media (Vector Laboratories, Burlingame, CA) containing
DAPI was used to stain nuclei. Slides were visualized using Nikon Eclipse TE300
fluorescent microscope. A minimum of 100 cells were analyzed per culture for Iba-1
staining using Adobe Photoshop CS4.
MTT Assay
Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (Sigma-Aldrich, St. Louis, MO). Primary glioma cultures were
seeded at a density of 1000 cells/ well in 96-well plates. A 50 μl stock solution of Dex
(Sigma-Aldrich, St. Louis, MO) was prepared by dissolving Dex in DMSO. Cells were
allowed to attach overnight and Dex or vehicle control was added to the appropriate
wells. After 3 days of drug exposure, MTT was added to wells and allowed to incubate
for 3 hr. Afterwards, the media was carefully aspirated and the purple formazan crystals
were dissolved in 100 μl DMSO (Fisher Scientific Co., Fair Lawn, NJ). Absorbance was
measured at wavelength of 570/690 nm using a FLx800 fluorescence microplate reader
(BioTek Instruments, Inc., Burlington, VT).
Cell Cycle Analysis
The effect of Dex on cell cycle phase distribution was measured by flow
cytometry. Cells seeded on 10 cm plates at 4000/ml were allowed to attach to the plates
overnight and then treated with 0.1, 1 and 10 μl Dex for 3 days. After cell trypsinization
and washing in ice cold PBS, the cells were fixed in ice cold 70% ethanol for at least 1
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hr. Subsequently, the cells washed with PBS and stained with 0.05 mg/ml propidium
iodide (PI) in presence of 0.1 mg/ml RNAses and then analyzed using BD Accuri C6
flow cytometer (BD Bioscience, San Jose, CA). A quantification of different phases of
cell cycle (G0/G1, S, G2/M) was carried out using Modfit LT V2.0 (Verity Software
House, Tosham, ME).
Co-Culture Experiments
To determine the role of microglia in tumor cell proliferation, co-cultures of
microglia-tumor cells were generated. First, primary glioma cells were generated form
control tumor-bearing mice using papain dissociation system. Since, microglial cells
attach very well to the plate and are hard to trypsinize, we used this property to deplete
them by mild trypsinization and serial subculturing technique. Furthermore, microglial
cell content was determined using ICC. Glioma co-cultures containing 0%, 5 % or 10 %
BV2 microglial cells were generated (Figure 2-2). Pure glioma cultures and microglia
cultures were used as controls. For MTT cell viability assay, 250 cells/well in 96-well
plates were seeded and treated with 0, 0.001, 0.01, 0.1, 1, 10, 100 μM Dex for 3 days.
Additionally cell cycle assay was employed on single and co-cultures after 3 days of Dex
treatment with either 0 or 10 μM. Cell proliferation assays were performed as mentioned
above.
Q RT-PCR
Glioma conditioned media (CM) was obtained by growing 1 X105 glioma cells/ml
of a complete media without antibiotic for 48 hs. The collected CM was filtered (0.2 μm
filter) to remove cellular materials and stored at -20 °C. BV2 microglial cells were seeded
at 4 X104 cells/ml in the CM and incubated overnight to allow cell attachment. The
cultures were treated with 0 or 10 μM Dex for 3 days. Total RNA was extracted from
BV2 cell cultures and mouse tumor samples using Trizol reagent (Invitrogen, Carlsbad,
CA). The yield and purity of the RNA was confirmed using Nanodrop; ND-1000 V3,
spectrophotometer.
First, cDNA was synthetized using transcriptor first strand cDNA synthesis kit
(Roche Applied Sciences, Indianapols, IN) using 1 μg of RNA. Primer panels were
designed using Roche Universal Probe Library to detect M1- (iNOS, IFNγ, IL-1β, TNFα,
CD86) and M2- (Arg1, TGF-β, CD204, MMP9, IL-1ra) markers of microglia (Table
2-1). The housekeeping gene, TBP, was used to normalize genes. Expression Q RT-PCR
was performed using LC480 light cycler under the following conditions; 50 cycles of
amplification, activation step for 5 min at 95°C, annealing step for 30 sec 60°C and
finally extension step 72°C for 10 sec.
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Figure 2-2.

A cartoon illustrating tumor-microglia co-cultures.

Primary glioma cultures were passaged a few times in order to deplete microglial cells.
ICC was performed to confirm the depletion of microglial cells. Subsequently, BV2
microglial cells were mixed with glioma cells to create glioma co-cultures containing 0%,
5% or 10% microglial cells.
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Table 2-1.

Primer sequences used for RT-PCR.
Gene
symbol
Arg1

Gene name

Gene ID#

Probe

Primer sequence

Arginase

NM_007482.3

2

CD86

CD86 antigen

NM_019388.3

107

CD204

Macrophage scavenger
receptor 1
Interleukin 1 receptor
antagonist
Matrix
metallopeptidase 9
Nitric oxide synthase 2

BC003814

26

BC042532

34

NM_013599.2

19

NM_010927.3

13

NM_011577.1

72

TNFα

Transforming growth
factor, beta 1
Tumor necrosis factor

NM_013693.2

25

IL-1b

Interleukin 1 beta

NM_008361.3

38

F:GAATCTGCATGGGCAAC
R:GAATCCTGGTACATCTGGGAAC
F:GAAGCCGAATCAGCCTAGC
R:CAGCGTTACTATCCCGCTCT
F:GGGAGTGTAGGCGGATCA
R:GGAGATGATAGTAGGGTGCTCTG
F:GGCAGTGGAAGACCTTGTGT
R:CATCTTGCAGGGTCTTTTCC
F:ACGACATAGACGGCATCCA
R:GCTGTGGTTCAGTTGTGGTG
F:CTTTGCCACGGACGAGAC
R:TCATTGTACTCTGAGGGCTGAC
F:TGGAGCAACATGTGGAACTC
R:GTCAGCAGCCGGTTACCA
F:CTGTAGCCCACGTCGTAGC
R:TTGAGATCCATGCCGTTG
F:AGTTGACGGACCCCAAAAG
R:AGCTGGATGCTCTCATCAGG

IL-1ra
MMP9
iNOS
TGFβ
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Statistical Analysis
Mann-Whitney U test was used to compare between two groups. Significance was
declared when p < 0.05. All statistical analyses were performed using Statistica 8
(StatSoft Inc., Tusla, OK).
Results
Generation of PDGF Driven Mouse Model of Glioma
In the current study we used a mouse model of glioma that is driven by PDGF
overexpression in neural stem cells. First, DF-1 cells were infected with RCAS PDGF or
GFP vectors. Fluorescent images of DF-1/GFP cells showed nearly 100% transfection
efficiency of the cells (Figure 2-3A). Virus producing cells, DF-1/PDGF, were injected
intracranially in Ink4a/Arf-/-/Ntva+ mice. The developed gliomas closely represent the
pathological features of human GBM such as vascular proliferation and the formation of
pseudopalisading necrosis structures as described previously (Figure 2-3B) [81].
Quantification of Cell Proliferation and Cell Death in Dex Treated Glioma-Bearing
Mouse
The precise effect of Dex on tumor cell proliferation remains unclear. Some
studies showed that Dex decreases cell proliferation, while others showed that Dex can
stimulate cell growth in vitro at low doses and is cytotoxic at high concentrations
[35,36,77]. To address this question, paraffin embedded glioma sections from mice
treated with 0 or 10 mg/kg Dex were subjected to IHC analysis. Anti-PCNA (Figure
2-4A) and anti-Ki67 (Figure 2-4B) primary antibodies were used to specifically quantify
proliferating cells. We found that there was a significant decrease of both markers in Dex
treated animals (p = 0.03 and p = 0.045 respectively). Then we examined cell death
induced by Dex treatment via quantification of caspase 3, as a marker of apoptosis, in
tumor sections. We observed low levels caspase-3 staining in both treated and control
tumor sections, but there was no significant difference between the two groups (p =
0.521) (Figure 2-4C). As a second measurement of cell death, total area of necrosis has
been quantified in tumor sections (Figure 2-4D). We found no significant difference in
necrosis regions between the two groups (p = 0.902). To determine whether Dex
decreases glioma cell proliferation, double immunofluorescence staining was performed
using anti-olig2 antibody to identify tumor cells and anti-PCNA antibody as a
proliferative marker. In agreement with DAB staining, there was a significant decrease in
total cell proliferation in Dex treated mice (p = 0.0079) (Figure 2-5A). More
interestingly, there was a significant decrease in proliferation in Olig2 positive cells (p =
0.0079) (Figure 2-5B). However, it is becoming widely accepted that tumor cell growth
is greatly influenced by microglial cells [79,86]. Therefore, we investigated the effects of
Dex on microglial cell content in tumor sections.

21

Figure 2-3.

PDGF-induced mouse model of glioma.

A, DF-1 chicken fibroblast cells were infected with RCAS/PDGF or RCAS/GFP vector.
DF-1/GFP cells were used to confirm transfection efficiency using Nikon eclipse TE300
fluorescent microscope 20X objective. B, H&E staining of tumor sections showing
vascular proliferation (left panel) and areas of necrosis area in the right panel (white
arrows).
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Figure 2-4.

IHC analysis of cell proliferation.

A, PCNA staining was significantly reduced in Dex treated tumor sections compared to
the control sections (P = 0.03948). B, Ki67 staining showed that Dex treated mice had
significantly less proliferating cells compared to the controls (P = 0.045). C, Cell death
was quantified using anti-cleaved caspase-3 primary antibody. The percentage of
caspase-3 positive cells was very low in both treated and control tumor sections and there
was not a significant difference between groups (P = 0.521). D, Total areas of necrosis
were not significantly different between Dex treated and control mice (P = 0.9015). Bars
represent the means; whiskers represent the standard deviation (±); * p < 0.05.
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Figure 2-5.

IHC analysis of glioma cell proliferation.

Tumor sections were double stained with anti-Olig2 (marker of glioma cells) and PCNA
(proliferative marker) primary antibodies. A, Total PCNA+ cells were significantly lower
in Dex treated samples compared to the controls (P = 0.0079). B, There was a significant
decrease in the proliferation of Olig2+ cells after Dex treatment (P = 0.0079). Nuclei
stained in blue (DAPI), PCNA stained in green (Alexa fluor 488) and Olig2 stained in red
(Alexa fluor 555); (Zeiss LSM 700 Laser Scanning Microscope, 400x magnification).
Bars represent the means; whiskers represent the standard deviation (±); * p < 0.05.
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IHC Analysis of Microglial Cell Number and Proliferation Following Dex
Treatment
To determine the effect of Dex on microglial cell content in the tumor
microenvironment, IHC analysis was employed to quantify microglial cells in tumor
sections. Using anti-Iba-1 primary antibody to specifically stain microglia/macrophages.,
there was a significant reduction in Iba-1+ cells in Dex treated tumor sections when
compared to the untreaded mice (p = 0.0299) (Figure 2-6A). Next we investigated
whether the decrease in microglial cell content is accompanied with a decrease in
microglial cell proliferation. To test this possibility, tumor sections from both control and
Dex treated mice were double stained with anti-Iba-1 and anti-PCNA primary antibodies.
Indeed, there was a significant decrease in microglial proliferation in the Dex treated
group when compared to the control group (p = 0.0138) (Figure 2-6B).
Gene Expression Analysis of Markers Associated with M2- and M1-Like Microglia
Phenotypes
In the tumor microenvironment, microglial cells are being reprogrammed by
glioma cells to create an immunosuppressive environment as well as to promote tumor
cell growth and invasion [78]. This type of activated microglia is known as M2-like
microglia. In contrast M1-microglia are characterized by immune reactivity and induction
of inflammation responses [78]. Therefore, we first analyzed microglial cell polarization
to both phenotypes in our glioma mouse model. Total RNA was extracted from tumor
samples obtained from control tumor-bearing mice using trizol method. We employed Q
RT-PCR to assess the expression of various genes that are related to M2- (Arg1, TGF-β,
CD204, MMP9, IL-1ra) and M1- (iNOS, IL-1β, TNFα, CD86) phenotypes. There was an
obvious overexpression of TGF-β, MMP9 and Arg1 were expressed at high levels when
compared to any of M1-markers that have been tested (Figure 2-7). CD204 is a cell
surface marker of M2-cells and showed a similar level of expression to iNOS and higher
expression compared to other M1-markers; IL-1β, TNFα, CD86. In agreement with
previous findings, tumor associated microglial cells exhibit on M2-like phenotype, which
could promote tumor cell proliferation and progression [79,86]. However, we observed a
decrease in tumor cell proliferation in Dex treated group, therefore we investigated
whether Dex exhibits its anti-proliferation properties by modulating M2-like phenotype
of microglial cells.
The Effect of Dex on Microglial Cell Polarization
We assessed gene expression of M1- and M2-signature genes in BV2 microglial
cultures. The cells were grown in glioma CM and treated with 0 or 10 μM Dex for 3
days. Total RNA was extracted using Trizol method, and Q RT-PCR was employed using
1μg of cDNA. Dex treatment resulted in a significant decrease (p ≤ 0.005) in relative
gene expression of M2-associated genes (i.e. CD204, TGFβ, MMP9 and IL-1ra) when
compared to the controls (Figure 2-8A). Next, we examined gene expression in vivo
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Figure 2-6. IHC analysis of microglial cell number and proliferation following
Dex treatment.
A, Total number of microglial cell was quantified in paraffin embedded tumor sections
stained with anti-Iba-1 primary antibody. Dex significantly reduced microglia content in
vivo (p = 0.0299). B, Tumor sections were double stained with anti-Iba-1 antibody as a
marker of microglial cells and PCNA as a proliferative marker. There was a significant
reduction in the proliferation of microglial cells after Dex treatment (P = 0.0138). Nuclei
stained in blue (DAPI), PCNA stained in green (Alexa fluor 488) and Iba-1 stained in red
(Alexa fluor 555); nuclei stained in red (Zeiss LSM 710 Laser Scanning Microscopes,
400x magnification). Bars represent the means; whiskers represent the standard deviation
(±); * p < 0.05.
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Figure 2-7. Q RT-PCR analysis of the genes associated with M1- and
M2-microglial phenotypes.
Total RNA was extracted from tumor-bearing mice and Q RT-PCR was performed using
Taqman probes. M2-markers of microglia (TGFβ, MMP9, Arg1, and CD204) were
overexpressed compared to M1-markers (iNOS, TNFα, IL-1β and CD86). Bars represent
the means; whiskers represent the standard deviation (±).
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Figure 2-8. Q RT-PCR analysis of genes associated with microglial polarization in
control and Dex treated tumor samples.
Total RNA was extracted from BV2 microglia cultures that were grown in glioma
conditioned media and treated with 0 or 10μM Dex for 3 days. In addition, RNA was
extracted from tissue samples of tumor-bearing mice treated with 0 or 10 mg/ml Dex. Q
RT-PCR was employed to analyze a panel of genes associated with M2- and
M1-phenotypes of microglia. A, Relative gene expression analysis showed that Dex
treatment significantly decreased M2-associated genes (i.e. CD204, TGFβ, MMP9, and
IL-1ra) in BV2 microglial cultures. B, The same trend was observed in glioma samples.
There was a decrease in MMP9, IL-1ra and Arg1 relative expression compared to TBP.
C, Dex treatment was associated with a significant decrease of all M1-associated genes
(i.e. CD86, iNOS, TNFα, IL-1β) in vitro. D, However, in Dex treated animals, while
there was no change in the relative expression of CD86 and iNOS, there was a significant
increase in TNFα and IL-1β expression. Bars represent the means; whiskers represent the
standard deviation (±); * p < 0.05.
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using glioma samples from control and Dex-treated mice. Consistent with the in vitro
results, Dex treatment was associated with an inhibition of M2-like microglial cells.
There was a modest decrease in relative gene expression of MMP9 and IL-1ra (Figure
2-8B). In BV2 cultures, the relative expression of M1-signature genes including CD86,
iNOS, TNFα and IL-1β significantly was decreased in Dex treated samples (p ≤ 0.005)
(Figure 2-8C). In contrast to in vitro results, there was a significant increase in the
expression of inflammatory cytokines; TNFα and IL-1β (p ≤ 0.01) (Figure 2-8D). The
expression of CD204 or CD86 surface markers of M2- and M1-like microglial cells,
respectively, was not altered in Dex treated tumor-bearing mice. Finally, we observed a
slight increase in expression of TGFβ and iNOS in Dex treated mice compared to the
control mice. Whether the decrease in M2-like microglial cells in tumor
microenvironment could play a role in the decrease of tumor cell proliferation remains to
be elucidated.
In Vitro Proliferation Assessment of Primary Mixed Glioma Cultures
Theoretically, Dex’s inhibitory effect on M2, pro-tumor, microglial cells could
play a role in the inhibition of tumor cell proliferation. To investigate this hypothesis, we
established primary glioma cultures from control tumor-bearing mice. Glioma cultures at
low passages (1-3) were used as in vitro model of mixed cultures of both tumor and
stromal microglial cells. To test the ability of maintaining microglial cells in vitro, we
performed ICC staining for microglia in these cultures. MTT cell viability assay was
employed on glioma cultures treated with escalating doses of Dex (0.001- 100 μM). For
all glioma cultures tested, there was no inhibitory effect of Dex (Figure 2-9A).
Additionally, ICC staining showed the presence of microglial cells (6%) (Figure 2-9B).
Furthermore, cell cycle analysis was performed on glioma cultures at low passages
treated with physiologically relevant Dex doses (i.e. 0, 0.1, 1 and 10 μM) for 3 days by
flow cytometry based technique. Although there was an a slight increase in the
percentage of G1 phase after Dex treatment, which might imply a cell cycle arrest, this
subtle increase may not be biologically important (Figure 2-9C). In addition ICC
staining demonstrated the presence of 10% Iba-1+ cells in this culture (Figure 2-9D).
Therefore, in vitro cell proliferation assays did not indicate a change in the proliferation
of mixed primary glioma cultures. To further validate our findings, we generated
microglia-glioma co-cultures and compared it to pure glioma cultures to address the
question of whether Dex influences tumor cell proliferation indirectly by affecting
microglial cells.
The Effect of Dex on Glioma-Microglia Co-Cultures
To determine the role of microglia in the cross talk between microglia and tumor
cells, co-cultures of microglia-tumor cells was generated (Figure 2-2). Primary mouse
glioma cultures were sub-cultured several times in order to deplete microglial cells. ICC
staining using anti-Iba-1 primary antibody was used to confirm the depletion of
microglial cells (Figure 2-10A). Subsequently, BV2 microglial cells were added to the
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Figure 2-9.

In vitro cell proliferation assays using primary mixed glioma cultures.

A, MTT assay for cell proliferation in vitro. Dex did not show an effect on cell
proliferation in vitro after 3 days of incubation. B, ICC staining for Iba-1+ cells showed
6% of a microglial cells in primary mouse glioma cultures. C, Cell cycle analysis was
performed on glioma cultures treated with 0.1, 1 and 10μM of Dex for 3 days. Although
there was an increase in G1 phase and a subsequent decrease in G2 phase, the observed
difference was not considered to be biologically significant. D, ICC staining for Iba-1+
cells showed 10% of a microglial cells in primary mouse glioma cultures. Bars represent
the means; whiskers represent the standard deviation (±).
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Figure 2-10. The effect of Dex on glioma-microglia co-cultures.
A, ICC staining for Iba-1+ cells showed a microglial cells depletion in primary mouse
glioma cultures. B, Glioma and microglial single cultures and co-cultures were plated in
96-well plates and treated with escalated doses of Dex for 3 days. There was not decrease
in cell viability under any of the conditions tested. C, Glioma and microglial single
cultures, and co-cultures were subjected to cell cycle analysis assay to assess the effect of
Dex on cell proliferation. We have not observed any Dex induced cell death (Sub-G1) or
cell cycle arrest at either G1 or G2 phase of the cell cycle. Bars represent the means;
whiskers represent the standard deviation (±).
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Figure 2-10. Continued.
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glioma cultures at 0%, 5% or 10% and seeded in 96-well plates for MTT assay or T75 for
cell cycle assay. Single cultures of glioma and BV2 cells were used as controls. After
overnight incubation to allow cell attachment, the cultures were treated with Dex for 3
days. The percentage of cell viability of all the cultures did not decrease when treated
with 0.001-10 μM Dex. Only at 100 μM, Dex was able to reduce cell viability of
microglia and co-cultures. However, 100 μM is not a physiologically relevant dose of
Dex (Figure 2-10B). Quantification of various phases of cell cycle did not reveal a
dramatic change in glioma cell proliferation either in single cultures or co-cultures with
microglial cells. However, we observed a subtle increase, in the G2/M phase after Dex
treatment in glioma cells co-cultured with 10% microglial cell (Figure 2-10C). This
might indicate a modest cell cycle arrest at G2 phase of the cell cycle. However, Dex
significantly increased microglial cell proliferation when not co-cultured as well as 5%
co-culture as shown by decreasing G0/G1 phase and increasing S phase. This effect has
not been observed in MTT assay or in vivo results, which emphasize the importance of
the native microenvironment to the tumor cell responsiveness.
Discussion
GBM is one of the most devastating types of cancer, because it has a very poor
prognosis. For the past 10 years, the overall survival has not improved, with estimated
survival of 3 years for only 7% of the patients [2]. Furthermore, all aggressive gliomas
develop vasogenic edema. These corticosteroids have been used to, quickly, improve
neurological symptoms resulting from edema formation [9,72]. However, the use of
corticosteroids has been associated with numerous side effects including behavioral
changes, peptic ulcer, hyperglycemia, weight gain and others [9,10]. Despite the intensive
use of Dex in the clinic, its exact effect on the biology of glioma disease is not precisely
identified. This is particularly important in regard to the effect of Dex on the
responsiveness of glioma to chemo- and radiotherapy. Therefore, the aim of the current
study is to investigate the effects of Dex on glioma and microglial cells in a
PDGF-induced glioma mouse.
The Anti-Proliferation Properties of Dex
Whether Dex has anti-proliferative or anti-neoplastic properties, or it stimulates
cell growth has been a long debate in the literature [35,36,76,77]. To understand the
effect of Dex on cell proliferation, we employed a mouse model that resembles the
human disease. To our knowledge this is the first study that utilizes a relevant mouse
model of glioma to study the action of Dex in this mouse model. Overexpressing PDGF
oncogene in neural stem cells using ink4a/Arf -/- mice drives the gliomagenesis in 100%
of mice, 6 week post-infection [82]. The uniqueness of this model is that it is closely
mimicking the molecular and pathological features of human GBM [81]. In addition, we
employed physiological doses of Dex in our studies. Therefore, in the current study mice
will be treated with a clinically relevant concentration of Dex (10 mg/kg) every day for 3
days. The human equivalent dose of 10 mg/kg is 0.8 mg/kg [83]. Indeed, at the time of
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clinical presentation, patients received 16-100 mg/day of Dex (0.27-1.67 mg/kg)
[9,83,87,88].
In our genetically engineered mouse model, we found that Dex treatment
decreases tumor cell proliferation as shown by PCNA and Ki67 IHC staining (Figure 2-4
and Figure 2-5). However, we did not observe significant levels of cell death in Dex
treated samples. This indicates that Dex exhibits anti-proliferative activity in our mouse
model. This finding can be interpreted in different ways. On one hand, several studies
showed a strong correlation between PCNA proliferation index and patient’s survival. In
particular, better prognosis and improved patient survival are correlated with low
proliferative index [89-91]. However, cancer therapeutics often target rapidly dividing
cells, it becomes quite possible that Dex might compromise the responsiveness of tumor
cells to chemotherapy and/or radio-therapy by slowing down tumor cell replication.
Indeed, the use of corticosteroids was shown to increase tumor’s radioresistance and
chemoresistance [37,92,93]. GBM and fibroblast cell lines did not acquire resistance to
ionizing radiation, whereas some of the carcinoma cell lines did [37,94]. Upregulation of
steroids receptors following ionizing radiation therapy may be a potential mechanism
responsible for Dex-induced radioresistance [38]. Such findings highlight the desperate
need to understand the exact effect of Dex on tumor cells especially for patients
undergoing chemotherapy or radiotherapy concurrently with corticosteroids.
The mechanism of how Dex alleviates cerebral edema is mostly unknown.
However, it has been proposed that Dex might improve peritumoral edema through its
anti-inflammatory effect or by inhibiting microglia cells [68,73]. Microglial cells are the
dominant immune cells in the brain, comprising 5-20% of total glial cells and up to
approximately 35% in the glioma [95,96]. In the current study, we found that Dex
decreases microglial cell content in tumor sections as confirmed by anti-Iba-1 primary
antibody (Figure 2-6A). Perhaps this decrease in microglial cell content is due to slowing
the proliferation rate (Figure 2-6B). However, two different phenotypes of microglial
cells exists; M1 and M2. M1-like microglial cells are known to possess pro-inflammatory
properties. On the other hand, various studies suggested that tumor-associated microglia
could support the tumor proliferation and growth, and possess an M2-like
anti-inflammatory phenotype [78,97,98].
Tumor Associated Microglial Cells Possess M2-Like Phenotype
In agreement with previous findings, we found that tumor associated microglia
exhibit an M2-phenotype in PDGF-induced gliomas (Figure 2-7). Assessment of
M1- and M2-signature gene expression reveals a shift in the microglia phenotype towards
less M2-like (MMP9 and IL-1ra) in both in vitro and in vivo samples upon Dex treatment
(Figure 2-8A). On the other hand, the expression of M1-associated genes was
inconsistent when in vitro data was compared to in vivo gene expression (Figure 2-8B)
raising the concern of the reliability of the in vitro models. We observed a decrease in the
expression of IL-1ra and Arg1, anti-inflammatory genes, in Dex treated tumor samples.
Of notice, IL-1ra is an antagonist to IL-1β and Arinase1 competes with and iNOS
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substrate [99,100]. When this finding is combined with the observed modest increase in
TNFα and IL-1β pro-inflammatory cytokines, it becomes quite obvious that Dex might
not relieve the edema through its anti-inflammatory effect. However, our study was
conducted after 3 days of Dex treatment, it would be very interesting to investigate the
effect of Dex on microglial cell polarization over a prolonged period of time.
Dex Decreases Microglial Cell Polarization to M2-Phenotype
Interestingly, Dex treatment was associated with a decrease in MMP9 expression,
possibly leading to suppression of glioma invasion. MMP9 is a member of matrix
metalloproteinases family, which is produced primarily by immune cells such as
macrophages/microglias and neutrophils [101]. MMP9 plays a pivotal role in tumor
progression and invasion [97]. MMP9 deficient mice had less lung metastases in both
melanoma and lung carcinoma animal models [102]. More importantly, MMP9 plays an
important role in angiogenesis and induction of cell proliferation [101,103,104]. These
findings raise the question of whether this decrease in M2-pro-tumor phenotype could
play a role in tumor cell proliferation in Dex treated samples. Therefore, we investigated
the anti-proliferative effect of Dex using low passage glioma cultures containing both
tumor and microglial cells. Quite unexpectedly, we could not detect a cell proliferation
inhibition following Dex treatment (Figure 2-9). We tested several cultures that contain
variable percentages of microglial cell. However an anti-proliferative effect of Dex was
not detected. To further elucidate the potential role of microglia in tumor cell
proliferation, we established glioma-microglial cells cultures and examined glioma cell
proliferation in Dex treated culture with and without microglial cells. However, we could
not detect a decrease in the proliferative capacity of either glioma nor microglial cells as
single or co-cultures. On the other hand, our in vivo data confirm a decrease in
proliferation of both cell types following Dex treatment. These contradicting findings
highlight the difference between in vitro and in vivo conditions and this does not
eliminate the possibility that microglial cell play an important role in supporting tumor
cell proliferation.
In conclusion, Dex treatment is associated with a decrease in tumor and
microglial cell proliferation in PDGF-driven glioma samples. Furthermore, pro-tumor
microglial phenotype, M2 seems to decrease after Dex treatment. Taken together, Dex
might act against glioma favorable conditions in our mouse model. However, this effect
might or might not be recapitulated when Dex is combined with DNA damaging agents
such as ionizing radiation. The current study shows the importance of studying the exact
mechanism of action of Dex in the context of glioma.
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CHAPTER 3.

THIOPURINE-INDUCED TOXICITY IN ASTROCYTES IS
DEPENDENT ON TPMT ACTIVITY*
Introduction

TPMT History and Discovery
Thiopurine methyltransferase (TPMT) has been studied extensively because of its
critical role in the methylation of thiopurine agents and their subsequent metabolites.
Primarily, this biotransformation leads to the inactivation of these agents. Thiopurine
drugs, such as thioguanine (TG), mercaptopurine (MP) and azathiopurine (AZA) are
widely used as anticancer and anti-inflammatory agents and as immunosuppressants.
However, since the use of these agents has been linked with the development of
secondary brain tumors in TPMT-deficient patients, it is pivotal to understand the toxicity
effects of thiopurines in the brain [42,47].
The activity of partially purified human TPMT was studied for the first time in
1978 [105] and the first application of activity measurements was done in 1980 [106].
These studies raised the possibility that human RBC TPMT activity is inherited and
TPMT genetic polymorphism is contributing to inter-individual differences in the
metabolism of thiopurines. It was not until 1995 that the first inactive TPMT allele had
been identified [107]. TPMT is found in the cytoplasm of eukaryotes and prokaryotes
[108]. It catalyzes S-methylation of aromatic and heterocyclic compounds (including
thiopurines) using S-adenosyl-L-methionine [41] however, the endogenous substrate for
TPMT is yet to be identified. Human TPMT gene has 10 exon and is located in
chromosome 6p22.3 [109,110]. The gene encodes a 28 kDA protein and is comprised of
245 amino acids [111].
Metabolism of Thiopurine Drugs
Thiopurines are pro-drugs that must be metabolized intracellularly by
hypoxanthine phosphoribosyl transferase (HPRT) to TG nucleotides (TGN) to exert their
cytotoxic effect [39]. First, AZA can be converted non-enzymatically to MP, which is
then converted to thioinosine monophospahte (TIMP) by HPRT (Figure 3-1). The same
enzyme catalyzes the conversion on TG to thioguanosine monophospahte (TGMP).
Thioxanthiosine monophosphate (TXMP) and inositol monophosphate dehydrogenase
(IMPDH) catalyze the conversion of TIMP to TGMP, which is subsequently converted to
TGN. TGN is a good substrate for DNA polymerases and hence is incorporated into
-----------------------------------*

Adapted with permission from Hosni-Ahmed A, Barnes JD, Wan J, Jones TS (2011) Thiopurine
methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after
thioguanine exposure. PLoS ONE 6: e29163.
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Figure 3-1.

Thiopurine drug metabolism pathway.

Azathioprine (AZA) is a prodrug of mercaptopurine (MP). Thioguanine (TG) and MP
can be converted by hypoxanthine phosphoribosyl transferase (HPRT) to thioguanine
nucleotide (TGNs) metabolites. MP can also be converted to the methylthioinosine
monophosphate (meTIMP) by thiopurine methyltransferase (TPMT), which is purine
synthesis inhibitor; however, thioguanine bypasses the conversion to this metabolite.
Thiopurines can be converted to inactive metabolites [i.e. methyl-mercaptopurine
(meMP); methyl-thioguanine (meTG); and methyl-thioguanine nucleotides (meTGNs)]
by TPMT. TGN metabolites can be incorporated into DNA and RNA leading to cell
death. However, DNA incorporation is believed to be the primary mode of cytotoxicity.
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DNA. At steady state levels, approximately 105 to 106 TGN incorporates into DNA per
cell [112,113]. However this level of DNA incorporation is tolerated by the cell and
further modification, via non enzymatic methylation, of TGN (me-TGN) is required for
its toxic effects. Me-TGN could induce single strand breaks in the DNA, interstrand cross
links and sister chromatid exchange [114-117]. On the other hand, thiopurine agents and
their metabolites can be inactivated by xanthine oxidase and, more importantly, TPMT
into thiopuric acid and 6-methyl derivatives respectively. Therefore, TPMT activity is
inversely correlated with TGN and toxicity levels [118].

TPMT Genotypes
The heterogeneity in TPMT activity is predominantly due to single nucleotide
polymorphisms (SNPs). Despite the fact that 29 TPMT variant alleles have been
identified [119], TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C variants account for
approximately 90% of cases with reduced enzymatic activity [43,120-124]. TPMT*2, the
first variant allele discovered, consists of G238C SNP which results in Ala80Pro amino
acid substitution [107]. This substitution leads to the distortion of the tertiary structure of
the TPMT protein and the loss of catalytic activity. However, the most clinically relevant
mutant allele is TPMT*3A which is characterized by two SNPs; G460A at exon 7 and
A719G at exon 10. These two SNPs result in Ala154Thr and Tyr240Cys amino acids
substitutions. Heterologous expression of human TPMT*2, TPMT*3A in yeast showed
enhanced proteolysis with a 15 min half live of the two mutant variants as compared with
18 hr for the wild-type TPMT [43]. When expressed in mammalian cells, TPMT*3B and
TPMT*3C variants, showed an enhanced degradation rate [125]. They consist of
individual Ala154Thr and Tyr240Cys SNPs, respectively.
The frequency of mutant TPMT variants differs among various ethnic
populations. For example, TPMT*3A is the most prevalent variant allele in American
Caucasian, Germans, Italians and Jordanians [126-129]. In addition, TPMT*3A is the
only detected variant allele in West Asia population [130]. However, TPMT*3A is
predominant in African-Americans, Egyptians and Ghanaians [126,131,132].
Although TPMT genotypes are a good predictor of TPMT activity, non-genetic
factors might also influence the enzyme activity. For example, thiopurines have been
shown to induce TPMT activity [133]. On the other hand aspirin and sulfasalazine are
potent inhibitors of TPMT when co-administered with thiopurines [134].
TPMT Phenotypes
TPMT activity is the best predictor of thiopurine efficacy and toxicity. TPMT
deficient patients are at high risk of life threatening hematopoietic toxicity when treated
with a standard dose of thiopurine drugs, due to accumulation of TGNs at high levels
[44-46,135-137]. Weinshilboum and Sladek [106] reported a trimodal distribution in
TPMT activity. The level of TPMT protein expression is directly correlated TPMT
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protein activity. Approximately 90% of the population are homozygous for wild-type
(WT) TPMT alleles and have high TPMT activity, about 10% are hetrozygous with
intermediate protein activity and ~0.3% are homozygous for variant alleles, and lack
detectable enzyme activity. Enhanced TPMT protein degradation, as compared to the WT
TPMT, has been shown to be the mechanism that is responsible for low TPMT activity
caused by variant alleles [43].

TPMT Importance in the Clinical Settings
Thiopurines are antimetabolites that have been used as anti-cancer agents and as
immunosuppressants. Since the 1950s, thioguanine and mercaptopurine have been used
to treat childhood acute lymphoblastic leukemia (ALL) [55,56]. Several studies have
indicated inter-patient variability in TGN concentrations [137-140]. TPMT
polymorphisms and differences in 6-MP absorption could in part explain inter-patient
variability [46,118,141,142]. With regard to treatment outcome in children with ALL,
high TGN concentrations have been associated with a better relapse-free survival
compared to patients with lower TGN concentrations [137,143]. TPMT phenotype is a
good predictor for thiopurine efficacy and toxicity. For example, a better outcome is
associated with lower TPMT activity [41]. In general, mutant homozygous or
heterozygous patients with low TPMT activity should be treated with lower thiopurine
doses to avoid toxicity. Several studies have shown that TPMT deficient patients treated
with 6-MP and receiving cranial irradiation have a high incidence of secondary brain
tumors [47].
Azathioprine and 6-mercaptopurine are widely used to treat inflammatory bowel
disease. It has been shown that TPMT SNPs are associated with thiopurine-induced
adverse drug reactions and bone marrow toxicity but not hepatotoxicity or pancreatitis
[144]. In the same line of evidence, TPMT polymorphisms have been associated with
azathioprine toxicity in renal transplant recipient patients [145]. TPMT is constitutively
expressed in several tissues including blood, kidney, liver, and brain [146-150]. The
association of TPMT status with brain tumor risk after thiopurine exposure prompts the
question of whether TPMT genotypes can predict thiopurine drug phenotypes in
astroglial cells. The relevance of TPMT status to thiopurine-associated phenotypes in
important brain cell populations has not been studied. Indeed, the first step to address the
question of whether TPMT plays any role in brain cancer risk after thiopurine treatment
is to determine whether TPMT phenotypes in the brain are similar to those from other
tissues. Thiopurine drug-associated genotoxicity has been linked to mutagenesis and
transformative events [151-153]. We hypothesize that TPMT deficiency can lead to
greater genotoxicity (i.e. DNA damage) and cytotoxicity in astroglial cells after
thiopurine exposure. To address this hypothesis we used primary astrocytes isolated from
transgenic mice of each TPMT genotype and performed in vitro studies to compare
thiopurine-induced cytotoxicity and DNA damage between TPMT genotypes. We also
used established human glioma cell lines as model astroglial cells to validate the findings
observed in primary mouse astrocytes.
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Methods and Materials
Animals
The TPMT knockout mice were a generous gift of Dr. Mary Relling (St. Jude
Children's Research Hospital). The TPMT +/-, and TPMT -/- mice were indistinguishable
from TPMT +/+ mice by appearance, life span, and organ histology (i.e. brain, liver,
spleen, intestine, thymus, and lymph nodes). Animals were maintained in accordance to
NIH guidelines for the care and use of laboratory animals and were housed in an
AAALAC accredited facility. The University of Tennessee Health Science Center
Institutional Animal Care and Use Committee approved all animal procedures.
Primary Astrocyte Cultures and Cell Lines
Astrocyte cultures were established from 2-5 day old pups of each TPMT
genotype. The DNA extracted from tail snips was used to confirm TPMT genotype. A
dissecting microscope was used to remove the meninges and hippocampus, and the
cortices were mechanically dissociated. Subsequently, cultures were established and
maintained in Dulbecco’s modified Eagle’s medium/Ham's F-12 50/50 mix (Cellgro,
Hemdon, VA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100
IU/ml penicillin, 100 μg/ml streptomycin and 20 ng/ml epidermal growth factor
(Millipore Co., Bedford, MA) and grown in Primaria flasks, (BD Bioscience, San Jose,
CA). Cells were refed with 20 ng/ml epidermal growth factor after three days of
incubation, and the media was changed after five days. At passage 2 three individual
primary cultures of the same genotype were pooled and seeded for experiments. Only
cultures with greater than 80% astrocyte purity as determined by GFAP
immunohistochemistry were included in experiments.
The T98 and A172 human glioma cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). T98 cells were grown in
Minimum Essential Medium Eagle (Cellgro, Hemdon, VA), supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium
pyruvate, 100 IU/ml penicillin, and 100 μg/ml streptomycin. A172 cells were grown in
Dulbecco’s Modified Eagle’s Medium (Cellgro, Hemdon, VA), supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 μg/ml
streptomycin. All cell cultures were maintained at 37°C in a 5% CO2 humidified
atmosphere.
Lentiviral Transduction
Human TPMT cDNA was obtained by digesting pCMV6-TPMT plasmid
(OriGene Technologies, Inc., Rockville, MD) at the BamHI and EcoRI sites. TPMT
cDNA was then amplified by PCR, purified through agarose gel electrophoresis, and
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subcloned into BamHI and EcoRI sites of pLenti-pgk-puro vector (Viral vector core,
UTHSC) (Figure 3-2). The pLenti-TPMT-pgk-puro and pLenti-GFP-pgk-puro lentivial
vectors were produced in 293T cells [154]. The lentiviral vectors were used to transfect
the A172 cell line in the presence of 6 μg/mL polybrene (Sigma-Aldrich, St. Louis, MO).
Transfection efficiency was monitored by GFP expression using fluorescent microscope.
The mock- (A172mock) and TPMT-transfected (A172TPMT) cell lines were seeded for
experiments at comparable passage numbers and TPMT activity was measured prior to
the experiments.
Cell Proliferation Comparison
The doubling rates for primary astrocyte cultures were determined and used as an
index of cell proliferation. At passage two, 75,000 cells/well were seeded in duplicate
6-well plates. The cells from one well of each plate were harvested daily using 0.05%
Trypsin-EDTA (Gibco, Life Technologies Inc., Grand Island, NY) and viable cells were
counted by trypan blue. Doubling rates were calculated based on Equation 3-1. T2 =
Harvesting time, T1 = Initial time, N = Final cell concentration, and N0= Initial cell
concentration. The mean doubling rate was calculated from duplicate experiments.
Doubling time (hr) = (T2-T1)/ [log2 x (Log N-Log N0)]

(Eq. 3-1)

TPMT Activity Assay
Primary mouse astrocyte and human glioma cell lines were sonicated to perform
the TPMT activity assay. The level of TPMT activity was determined using a
non-chelated radiochemical assay [105,147] with minor modifications. TPMT activity
was quantitated by measuring the conversion of 6-mercaptopurine (Sigma-Aldrich, St.
Louis, MO) to radioactively labeled 6-methylmercaptopurine with [14C]
S-adenosyl-L-methionine (SAM) (Perkin Elmer, Waltham, MA). The protein
concentration of each lysate was measured prior to performing the assay and was used to
calculate TPMT activity. The mean activities for each genotype were calculated using
data from triplicate assays.
MTT Assay
Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, MO). In brief, 1000 cells were
seeded per well in 96-well plates. Plates were pre-coated with poly-L-ornithine
(Sigma-Aldrich, St. Louis, MO) and laminin (Invitrogen, Carlsbad, CA) for primary
astrocytes to facilitate cell attachment. A stock solution (15 mM) of TG (Sigma-Aldrich,
St. Louis, MO) was prepared by dissolving TG in 0.1 N NaOH. Cells were allowed to
attach overnight and TG or vehicle control was added to the appropriate wells. After five
days, MTT was added and allowed to incubate for 3 hr. The media was carefully
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Figure 3-2.

pLenti-pgk viral vector.

TPMT or GFP cDNA was subcloned into pLenti-pgk-puro vector using BamHI and
EcoRI sites. The lentivial vectors were packaged in 293T cells. The mock- (A172mock)
and TPMT-transduced (A172TPMT) cell lines were generated by transducing A172 cell
line with either pLenti-TPMT-pgk-puro or pLenti-GFP-pgk-puro lentivial
vector, respectively.
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aspirated and the purple formazan crystals were dissolved in 100 μl DMSO (Fisher
Scientific Co., Fair Lawn, NJ). Absorbance was measured using a FLx800 fluorescence
microplate reader (BioTek Instruments, Inc., Burlington, VT).
Alkaline Comet Assay
The comet assay was performed according to the protocol established by the
laboratory of Dr. Peter McKinnon (St. Jude Children's Research Hospital) [155]. In brief,
50,000 primary astrocyte or 30,000 human astroglial cells were seeded in Primaria
24-well plates (BD Bioscience, San Jose, CA) or in Falcon 24-well plates (BD
Bioscience, San Jose, CA), respectively. Cells were allowed to attach overnight and then
exposed to TG for three days. Thereafter, the cells were harvested and counted to prepare
a 3 x 105 cells/ ml suspension in PBS. The cell suspension was mixed with 1.2%
ultra-pure low melting point agarose (Invitrogen, Carlsbad, CA) and then casted onto
chilled fully frosted glass slides (Fisher Scientific Co., Fair Lawn, NJ) pre-coated with
0.6% agarose (Bio-Rad, Richmond, CA). The cells were lysed for 1.5 hr at 4°C in lysis
buffer (100 μM EDTA, 2.5 M NaCl, 10 mM Tris, 1.3% Triton X-100 and 3.3% DMSO).
The slides were washed twice with distilled H2O and incubated for 45 min at 4°C in
electrophoresis buffer (1 mM EDTA, 50 mM NaOH and 1% DMSO). Electrophoresis
was conducted at 12 V and ~90 mA at 4°C for 25 min. Slides were incubated for one hr
in 400 mM Tri-HCl neutralization buffer followed by a 20 min incubation in SYBR green
I (Sigma-Aldrich, St. Louis, MO). Images were captured using a Nikon Eclipse TE300
fluorescent microscope. All experiments were replicated using two different sets of
pooled cultures. The extent of DNA damage was expressed as the comet tail moment (the
amount and distribution of DNA in the tail). The comet tail moment was measured in a
minimum of 60 cells using CometScore version 1.5 (TriTek Corp., Sumerduck, VA).
Immunohistochemistry
Primary astrocytes were grown on poly-D-lysine chamber slides (BD Bioscience,
San Jose, CA) for GFAP staining (to confirm astrocyte purity) or on glass coverslips and
treated with 0 or 10 uM of TG for γH2AX staining. Cells were fixed with 4% PFA/PBS
for 10 min, permeabilized with 0.5% Triton X-100/PBS for 5 min. Cells were then
washed with PBS and blocked with 3% BSA/PBS for one hr. Cells were then
immunostained with either anti-GFAP in PBS (1:500; Sigma-Aldrich, St. Louis, MO) for
two hr or anti-γH2AX in 3%BSA (1:1000, Millipore Co., Bedford, MA) for one hr.
Subsequently, cells were washed with PBS and incubated for one hr with Cy2-conjugated
donkey anti-mouse secondary antibody (1:250 in PBS containing 2% donkey serum and
0.1% Triton X-100; Jackson Immuno Research Laboratories, West Grove, PA) for GFAP
or with donkey anti-mouse secondary antibody labeled with 1:800 Alexa 488 in 3% BSA
(Invitrogen, Carlsbad, CA) for one hr. Finally, vectashield mounting media (Vector
Laboratories, Burlingame, CA) containing propidium iodide was used to counterstain
nuclei. Slides were visualized using Nikon Eclipse TE300 fluorescent microscope. Slides
stained for γH2AX were analyzed for γH2AX foci and a minimum of 100 cells were
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analyzed per genotype. Cells containing fewer than five foci were excluded to normalize
for baseline staining observed in control treated cells. Cells with "pan-staining" were
considered to have more than 5 foci per cell. Hence, the percentage of cells with γH2AX
foci staining represents the percent of cells with greater than five foci per cell.
Statistical Analysis
Differences in cytotoxicity and DNA damage among all three groups were
compared using Kruskal-Wallis analysis of ranks (Analysis of variance). Mann-Whitney
U test was used when only two groups were compared. Significance was declared when p
< 0.05. All statistical analyses were performed using Statistica 8 (StatSoft Inc., Tusla,
OK).
Results
Characterization of TPMT +/+, TPMT +/-, and TPMT -/- Primary Mouse Astrocyte
Cultures
The primary mechanism of thiopurine cytoxicity is believed to be through
incorportation of TG nucleotide metabolites into DNA [39,152,156] (Figure 3-1), and
therefore is dependent on the rate of cell proliferation. Hence, we first compared the
doubling rates between TPMT +/+, TPMT +/-, and TPMT -/- primary astrocyte cultures.
Primary cultures were established from mouse cortices of each TPMT genotype and
astrocyte purity was confirmed by GFAP (glial fibrillary acid protein, an astrocyte
marker) fluorescent staining (Figure 3-3A) [157]. We found that there was no significant
difference in growth rates of the different TPMT genotypes (Figure 3-3B). The mean
doubling rates for TPMT +/+, TPMT +/- and TPMT -/- cultures were 33.9, 34.2, and 29.6
hr, respectively (p = 0.89). Next, we measured the level of TPMT protein activity using a
well-established radiochemical assay that measures the conversion of 6-mercaptopurine
to 6-methylmercaptopurine using [14C] S-adenosyl-L-methionine (SAM) as a methyl
donor [105]. In agreement with previous studies comparing protein activity in
hematological cells of different TPMT genotypes [121,150,158], protein activities in
astrocytes were significantly different according to TPMT genotype (Figure 3-3C).
TPMT +/+, TPMT +/-, and TPMT -/- primary astrocytes displayed high (7.6 unit/109μg
protein), intermediate (3.9 unit/109 μg protein), and low (0.25 unit/109 μg protein) levels
of protein activity, respectively (p = 0.018). Based on these data, we next determined
whether TPMT could modulate the cytotoxic effects of TG in primary astrocytes.
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Figure 3-3. Characterization of TPMT +/+, TPMT +/-, and TPMT -/- primary
astrocyte cultures.
A, The image (200x) of primary astrocytes showing high astrocyte purity determined by
GFAP (green) and propidium iodide (red) fluorescent staining. B, There was no
significant difference in growth rates between astrocyte cultures of each TPMT genotype
(p = 0.89). C, The level of TPMT protein activity was significantly different between the
three TPMT genotypes (p = 0.018); and levels were comparable to Nalm6 and CEM
control lymphoblastoid cell lines. Bars represent the means; whiskers represent the
standard deviation (±); * p < 0.05. Adapted with permission from Hosni-Ahmed A,
Barnes JD, Wan J, Jones TS (2011) Thiopurine methyltransferase predicts the extent of
cytotoxicty and DNA damage in astroglial cells after thioguanine exposure. PLoS ONE
6: e29163.
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Comparison of TG-Associated Cytotoxicity in TPMT +/+, TPMT +/-, and
TPMT -/- Primary Astrocyte Cultures
To determine whether TPMT could predict thiopurine cytotoxicity in primary
astrocytes, the MTT colorimetric assay was employed to compare TG sensitivity between
astrocytes of each TPMT genotype. This assay measures cell viability by quantitating the
extent at which metabolically active cells can reduce tetrazolium salt (MTT) to form
purple formazan crystals. Astrocytes were exposed to escalating concentrations of TG
(0.125, 1.25, 12.5, 25, 50, and 100 μM) for five days and then subjected to the MTT
assay. Cell viability data at each TG concentration was used to calculate IC50 values. As
expected, TG treatment resulted in cytotoxicity in a dose dependant manner (Figure
3-4A). Cell viability was significantly lower in TPMT +/- and TPMT -/- cultures at four
concentrations of TG (12.5, 25, 50, and 100 μM) when compared to TPMT +/+ cultures (p
< 0.04). Interestingly, TPMT +/- but not TPMT -/- astrocytes were significantly more
sensitive at 1.25 μM of TG than TPMT +/+ astrocytes (p = 0.004); and this finding was
reflected in corresponding IC50 values. There was a 2.9 fold reduction in IC50 in TPMT +/(3.5 μM TG) versus a 1.2 fold reduction in TPMT -/- (8.6 μM TG) when compared TPMT
+/+
astrocytes (10.3 μM TG); and the TPMT +/- and TPMT -/- IC50 values were
significantly different from TPMT +/+ (p < 0.05) (Figure 3-4B). Studies have shown that
genotoxicity (i.e. DNA strand breaks) correlates with cytotoxicity after TG exposure
[116,156]. Hence, we investigated whether the degree of TG-induced DNA strand breaks
was associated with the level of cytotoxicity in primary astrocytes.
Comparison of the Extent of DNA Damage Between TPMT +/+, TPMT +/-, and
TPMT -/- Primary Astrocytes
To address the question of whether the level of TG-induced cytotoxicity is
correlated with DNA damage, we employed the alkaline comet assay. This assay
quantifies DNA damage [i.e. single strand breaks (SSBs), double strand breaks (DSBs)
and alkali labile sites] using fluorescent microscopy to visualize the extent of DNA
migration from the nucleus of individual cells embedded in agarose [159]. We exposed
astrocytes to 5 μM of TG for 72 hr. IC50 data was used to select a dose that would allow
us to capture damage in each genotype. We observed a significant difference in DNA
damage between the three genotypes as measured by mean comet tail moment. Both
TPMT +/- and TPMT -/- astrocytes had a significantly greater degree of DNA damage than
TPMT +/+ astrocytes (mean comet tail moment = 2.64, 1.26, and 0.4, respectively; p =
0.033) (Figure 3-5A). In agreement with MTT studies, TPMT +/- astrocytes were more
sensitive to TG, as evidenced by a greater degree of DNA damage, than were TPMT -/astrocytes. The difference in DNA damage between TPMT +/- and TPMT -/- astrocytes
was not significantly different (p = 0.083). There was no difference in DNA damage
between TPMT genotypes of control treated astrocytes.
Studies have shown that the predominant DNA lesions caused by TG are SSBs
although some DSB lesions are formed [156]. Therefore, we then compared γH2AX (an
established DSB marker) foci staining after TG exposure to determine the extent of the
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Figure 3-4. Comparison of TG-induced cytotoxicity in primary astrocyte cultures
of each TPMT genotype.
A, Primary astrocytes of each TPMT genotype were exposed to thioguanine (TG) and
cell viability was determined using the MTT assay. TPMT +/- and TPMT -/- astrocytes
were significantly more sensitive to TG (12.5 - 100µM) than TPMT +/+ (p < 0.04). B, IC50
values were significantly different between the three genotypes (p = 0.027) and TPMT +/astrocytes were the most sensitive. Bars represent the means; whiskers represent the
standard deviation (±); * p < 0.05. Adapted with permission from Hosni-Ahmed A,
Barnes JD, Wan J, Jones TS (2011) Thiopurine methyltransferase predicts the extent of
cytotoxicty and DNA damage in astroglial cells after thioguanine exposure. PLoS ONE
6: e29163.
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Figure 3-5. Comparison of TG-induced genotoxicity in primary astrocyte cultures
of each TPMT genotype.
A, The alkaline comet assay was used to compare TG-induced DNA damage between
TPMT genotypes. TPMT +/- and TPMT -/- astrocytes had significantly higher mean comet
tail moments than TPMT +/+ astrocytes (p = 0.033). B, Immunoflourescence staining for
γH2AX confirms IC50 and comet data. TPMT +/- astrocytes had greater damage than
TPMT +/+(p = 0.03). Below are representative images of γH2AX staining for control
treated (left) and TG treated (right) astrocytes. γH2AX foci stained in green; nuclei
stained in red (Zeiss LSM 710 Laser Scanning Microscope, 400x magnification). Bars
represent the means; whiskers represent the standard deviation (±); * p < 0.05. Adapted
with permission from Hosni-Ahmed A, Barnes JD, Wan J, Jones TS (2011) Thiopurine
methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells
after thioguanine exposure. PLoS ONE 6: e29163.
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DNA lesions that are in the form of DSBs and whether this damage is different between
the TPMT genotypes. Astrocytes were seeded on glass coverslips and exposed to either 0
or 5μM of TG. We found that TPMT +/- astrocytes had the greatest degree of γH2AX foci
staining (19.4%) compared to TPMT +/+ (9.3%), and TPMT -/- (7.22%) (Figure 3-5B). In
agreement with comet data, TPMT +/- was the most sensitive genotype. There was a
significant difference between TPMT +/- and TPMT +/+ (p = 0.03), but no significant
difference was observed between TPMT -/- and TPMT +/+ cells.
Comparison of TG Phenotypes Between Human Glioma Cell Lines with Different
TPMT Protein Activities
Next, we conducted conducted MTT and comet assays to assess TG-induced
cytotoxicity and genotoxicity in human glioma cell lines with high and low TPMT
activity and compared TG-induced cytotoxicity and DNA damage between them. First,
we measured TPMT protein activity in four human glioma cell lines (T98, A172, U87,
and LN18) to identify high and low TPMT expressers. We chose T98 (10.48 unit/109 μg
protein) and A172 (6.15 unit/109 μg protein) as the high and low expressers, respectively
(Figure 3-6A). We then subjected T98 and A172 to the MTT assay to measure
TG-induced cytotoxicity. Both cell lines were exposed to increasing concentrations of TG
(0.15, 0.75, 1.5, 6.25, 12.5 and 25 μM) for five days. The cell viability was determined
for each concentration and these data were used to calculate IC50 values. As predicted by
TPMT activity and in agreement with MTT studies performed in primary astrocytes,
A172, the low TPMT expressing cell line, had significantly lower cell viabilities at each
TG concentration as compared to T98 (p < 0.005) (Figure 3-6B). The higher TG
sensitivity of A172 was also reflected in the IC50 values. A172 displayed a 6.9 fold lower
IC50 (1.2 μM) when compared to T98 (8.3 μM) (Figure 3-6C).
Next, we employed the comet assay to compare DNA damage between T98 and
A172 cultures exposed to 3μM TG for 72 hr. In agreement with the primary astrocyte
data, cells with low level of TPMT activity had significantly more DNA damage
compared to high TPMT activity (mean comet tail moment: A172 = 1, T98 = 0.3; p =
0.02) (Figure 3-6D). DNA damage in control treated cells was not significantly different
between the two cell lines.
Comparison of TG Phenotypes Between A172mock and A172TPMT Isogenic Cell Lines
To further validate our findings, TG-induced toxicity was compared using
isogenic cell lines with different TPMT activities. A172 cells were the lowest TPMT
expresser, hence we over-expressed TPMT protein in this cell line using lentiviral vector
and compared TG-induced cytotoxicity and DNA damage between the mock transduced
(A172mock) and TPMT transduced (A172TPMT) cell lines. Transduction efficiency was
monitored by GFP expression (Figure 3-7A). In addition, the level of TPMT protein
activity in A172TPMT was significantly higher as compared to A172mock (151.23 unit/109
μg protein versus 9.47 unit/109 μg protein, respectively; p < 0.05) (Figure 3-7B). We
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Figure 3-6.
lines.

Assessment of TPMT-associated phenotypes in human glioma cell

TPMT protein activity was measured in T98 and A172 glioma cell lines. A, T98
displayed a significantly higher level of protein activity than A172 (p < 0.05). B, As
observed in primary astrocyte cultures, low TPMT protein activity is associated with
greater cytotoxicity as determined by the MTT assay; C, and reflected in IC50 values.
A172 cells had a significantly more sensitive at all TG concentrations and lower IC50 than
T98 (p < 0.05). D, The alkaline comet assay was used to compare TG-induced DNA
damage. A172 displayed a significantly greater degree of TG-induced DNA strand breaks
than T98 (p = 0.02) as measured by mean comet tail moment. Bars represent the means;
whiskers represent the standard deviation (±); * p < 0.05. Adapted with permission from
Hosni-Ahmed A, Barnes JD, Wan J, Jones TS (2011) Thiopurine methyltransferase
predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine
exposure. PLoS ONE 6: e29163.

52

Figure 3-7.

TPMT-associated phenotypes in A172 isogenic cells.

TPMT was overexpressed in A172 cells using lentivial vector. A, Transduction efficiency
was monitored by GFP expression. B, TPMT protein activity was measured in A172mock
and A172TPMT cell lines. TPMT protein activity was significantly higher in A172TPMT (p
< 0.05). C, There were no significant differences in doubling times between A172TPMT
and A172mock (p = 0.38). D, A172TPMT showed a significantly higher resistance to
TG-induced toxicity when compared to A172mock as determined by the MTT cell viability
data (p < 0.005) and E, by IC50 values (p < 0.05). F, The alkaline comet assay was used
to compare TG-induced DNA damage. A172mock displayed a significantly higher DNA
damage than A172TPMT (p = 0.03) as measured by mean comet tail moment. Bars
represent the means; whiskers represent the standard deviation (±). * p < 0.05. Adapted
with permission from Hosni-Ahmed A, Barnes JD, Wan J, Jones TS (2011) Thiopurine
methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells
after thioguanine exposure. PLoS ONE 6: e29163.
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Figure 3-7.

Continued.
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performed growth rate studies and found that there were no difference in doubling times
between A172TPMT and A172mock (28.5 and 29.6 hr, respectively; p = 0.38) (Figure
3-7C). When A172mock and A172TPMT were exposed to increasing concentrations of TG
we found that A172mock had significantly lower cell viabilities at 0.75, 1.5, 6.25, 12.5 and
25 μM of TG as compared to A172TPMT (p < 0.005) (Figure 3-7D). These findings were
reflected in the A172TPMT IC50 value that was approximately two-fold higher than
A172mock (3.9 μM versus 1.9 μM, respectively; p < 0.05) (Figure 3-7E).
Next, we exposed A172TPMT and A172mock to 5 μM of TG for 72 hr and compared
the extent of DNA damage using the comet assay. We selected 5 μM based on the IC50
value of A172TPMT. As expected, A172mock had a significantly greater degree of DNA
damage when compared to A172TPMT (mean comet tail moment: A172mock = 0.7,
A172TPMT = 0.24; p = 0.03) (Figure 3-7F). DNA damage in control treated cells was not
significantly different between the two cell lines (p = 0.35). These data support our
findings observed in both the primary mouse astrocytes and the glioma cell lines (T98
and wild-type A172) that when TPMT protein activity is low a greater degree of
cytotoxicity and DNA damage can occur after TG exposure.
Discussion
TPMT is a cytoplasmic enzyme responsible for deactivating thiopurine drugs and
a low TPMT phenotype can lead to life-threatening hematological toxicities when
thiopurines are given. Indeed, chronic administration of thiopurines has been linked to an
increased risk of cancer including brain tumors [47,48,50,52,67]. Unfortunately, not all
patient populations that are treated with thiopurines are evaluated for their TPMT status
prior to initiating thiopurine therapy; hence, the importance of TPMT to
thiopurine-associated cancer risk is not clear. Since TPMT deficiency is relatively rare
across populations, it is difficult to assess the importance of TPMT status to thiopurine
therapy-related cancer risk. However, in a report by Relling et al. it was shown that
whether patients developed a brain tumor as a late complication of post-antileukemic
therapy depended on their TPMT status [47]. Patients who were determined to be at high
risk for treatment relapse received prophylactic cranial irradiation concurrent with
antimetabolite therapy; and those patients with a low TPMT had a surprisingly high
incidence of brain tumors as a late complication. Indeed, ionizing radiation is a risk factor
for brain tumorigenesis. However, in this report, patients with low TPMT had a 42.9%
incidence of brain tumors compared to 15.8% for those with high TPMT.
Astrocytomas are the most common brain tumor type that has been reported in
patients after thiopurine therapy [47,48,50,67]. To our knowledge, the importance of
TPMT status to thiopurine-associated phenotypes in astroglial cells has not been
investigated. We assessed TPMT and TG phenotypes in astroglial cells using primary
mouse astrocytes from different TPMT genotypes and human glioma cells that differ in
TPMT activity. In this study we have shown that TG induces cytotoxicity in a
dose-dependent manner in astroglial cells; and cells with a low TPMT phenotype
(TPMT+/- and TPMT -/- astrocytes and A172mock) were significantly more sensitive to TG.
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We also showed that TG exposure induced more DNA damage in the form of SSBs in
astroglial cells with low TPMT than in cells with high TPMT. DNA damage in the form
of DSBs was significantly different between astroglial cells with low and high TPMT.
SSBs have been shown to be the primary DNA lesion induced by thiopurine drugs [156].
Interestingly, we found that low but not the complete absence of TPMT sensitized
primary astrocytes to a higher degree of cytotoxicity and genotoxicity (i.e. IC50, SSBs and
DSBs) after TG exposure. This discordance could possibly be explained by the induction
of a compensatory mechanism that deactivates thiopurines upon the complete loss of
TPMT. Another possible explanation could be a defect in the mismatch repair (MMR)
system's ability to recognize DNA-TG nucleotide lesions. The MMR system is
responsible for recognizing DNA mis-pairing caused by DNA-TG nucleotides and the
subsequent signaling for cell death [160-163]. The latter possibility suggests that
astroglial cells with a defective TPMT activity could have DNA lesions persisting in the
genome that could potentially lead to mutagenesis and cancer. Interestingly, some studies
suggest that children with TPMT heterozygosity develop brain tumors and other cancers
more frequently than children with mutant TPMT. However, the frequency of
heterozygous or mutant TPMT is very low making it is difficult to make any definitive
conclusions [47,164]. It would be interesting to investigate whether TPMT status
influences the extent of TG nucleotide incorporation into DNA and damage recognition
by the MMR system as well as whether ionizing irradiation alone or in combination with
thiopurines results in similar findings.
In summary, chronic thiopurine therapy has been associated with the development
of brain cancer and TPMT status has been linked to brain tumor risk. We found that
TPMT is an important factor for thiopurine drug-induced cytotoxicity and genotoxicity in
astroglial cells. Because of the limited availability of human astrocytes we used human
glioma cell lines. Although glioma cells can exhibit a number of genetic alternations that
could contribute to the phenotypes observed, our study shows that TPMT is indeed an
important determinant of thiopurine toxicity.
Low TPMT can increase the level of TG-induced genotoxic damage in both
normal and in neoplastic astroglial cells. The observation that glioma cells can have
variable degrees of TPMT protein activity and that low protein activity can sensitize cells
to TG may suggest that thiopurines may potentially have a therapeutic role in low TPMT
expressing glial tumors. However, since thiopurine drugs are linked with secondary brain
tumors, we do not recommend the use of these agents in brain tumor treatment.
Furthermore, In vitro studies have shown that thiopurine drugs are associated with
mutagenic events in a variety of cell lines [116,151]. It is possible that the DNA damage
caused by low TPMT function can ultimately contribute to transformative events over
time. One study found that TPMT was not an important factor for cancer risk after
thiopurine therapy [164]; however in this study only TPMT genotype was determined
which may have excluded patients with discordance between TPMT genotype and
activity. Individuals who are wild-type for TPMT can display a wide variation in their
TPMT activity [127]. Further studies are needed to understand the importance of TPMT
in the brain when thiopurines are given. Whether these findings can be replicated in vivo
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and whether factors important to DNA repair mechanisms are responsible for the TG
phenotypes described in this study should also be investigated.
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CHAPTER 4.

SCREENING OF NOVEL ANTI-GLIOMA SMALL
MOLECULES*
Introduction

Significance of Glioma Disease
According to CBTRUS report, gliomas represent 80% of the malignant brain
tumor incidence in the United States [2]. Furthermore, the overall survival rate is 3 years
for less than 8% for grade IV GBM. On the global scale, the incidence of malignant brain
tumors is approximately 3 in 100,000 per year, with a higher rate in the developed
countries compared to the developing countries [4,5]. GBM is the most aggressive
subtype of brain tumor and is characterized by diffuse infiltration into normal brain
parenchyma making its resection very challenging. Consequently, these tumors can
repopulate after surgery, causing cancer relapse [3]. Typical treatment involves surgical
resection followed by cranial irradiation, which can alleviate the neurological symptoms
and seizures in glioma patients. In general, patients receive 54-60 Gy radiotherapy
regimen in 30 fractions during 6 weeks of treatment [3]. Usually concurrent TMZ therapy
of 75 mg /m2/day is given during the irradiation therapy followed by 28 cycles of
adjuvant TMZ therapy (150 mg/m2/day for 5 days/ week). Despite this aggressive
therapy, there has not been a significant improvement in either the prognosis or the
survival of patients. Therefore, there is an urgent need to find new therapeutical
approaches to improve patients’ survival and outcome. The current study focused on
assessing the potential anti-cancer activity of 2 classes of small molecules;
tetrahydroisoquinoline (THIQ) and chromene derivatives. A series of in vitro studies
were conducted as part of the screening process to find the most potent derivatives with
least toxicity to normal stromal cells.
Tetrahydroisoquinoline Derivatives
The laboratory of Dr. Duane Miller at UTHSC focuses on the synthesis of novel
compounds against a wide variety of diseases and disorders including gliomas. In 2006,
Mohler et al. have discovered novel THIQ derivatives that reduced cell viability in a rat
glioma cell model [165]. According to this study, compound 1 (EDL-155) was the most
toxic analog in glioma as well as lung, breast and cervical cancer cell lines. The IC50
values ranged from approximately 3-10 μM, depending on the cancer cell line. Therefore,
-----------------------------------*

Adapted with permission. Patil R, Hosni-Ahmed A, Jones T, Patil S, Asres L, et al. (2014)
Synthesis and In Vitro Evaluation of Novel 1,2,3,4-Tetrahydroisoquinoline Derivatives as Potent
Antiglioma Agents. Anticancer Agents Med Chem (In Press). Patil SA, Wang J, Li XS, Chen J,
Jones TS, et al. (2012) New substituted 4H-chromenes as anticancer agents. Bioorg Med Chem
Lett 22: 4458-4461.
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we were interested in investigating the anti-cancer activity of other THIQ analogs in a
panel of human glioma cell lines [166].
Chromene Derivatives
One of the limiting factors of cancer therapeutics is poor drug penetration.
Previous studies showed an improvement in drug penetration as well as efficacy when
Arginine-Glycine-Aspartic Acid (RGD) peptides were co-injected with anti-cancer drugs
[167]. Drs. Miller and Patil research groups used RGD and similar analogs to search
online libraries for similar anti-tumor small molecules [168]. From the 2 hits obtained,
GRI-394837, a chromene analog was subsequently investigated. Chromenes are analogs
of podophyllotoxin, a natural plant product, that have been isolated from Podophyllum
species [169]. Whereas, podophyllotoxin function in plants is not fully understood, its
semisynthetic analogs exhibit anti-cancer activity. Chromenes demonstrated high
efficiency as apoptosis inducers by inhibiting microtubule assembly and as vascular
disrupting agents (VDA) [170,171]. In the current study, several chromene derivatives
have been synthesized and their activities in glioma were assessed in vitro and in vivo.
Materials and Methods
Drug Preparation
THIQ and chromene small molecules have been synthesized in Dr. Miller and Dr.
Patil’s laboratories respectively at UTHSC. For in vitro screening, a freshly prepared 50
μM stock solution was prepared by dissolving EDL-360 in DMSO. EDL-291 was
dissolved in PBS to prepare 10μM stock solution. Other THIQs, chromenes and TMZ
compounds were dissolved in DMSO. A freshly prepared 100 μL stock solution was
prepared by dissolving the compound in DMSO. For treatment of tumor-bearing mice,
EDL-360 was dissolved in 0.9% saline, whereas SP-6-27 was dissolved in glacial acetic
acid.
Glioma Cell Lines and Primary Astrocyte Cultures
The human glioma cell lines, T98, U87 and LN18, were obtained from the
American Type Culture Collection (Manassas, VA, USA). A172 glioma culture was a
generous gift from Dr. C. Duntsch (Department of Neurosurgery, UTHSC). T98 and U87
cultures were grown in Minimum Essential Medium Eagle (Cellgro, Hemdon, VA),
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 0.1 mM nonessential
amino acids, 1 mM sodium pyruvate, 100 IU/ml penicillin, and 100 μg/ml streptomycin.
A172 cells were grown in Dulbecco’s Modified Eagle’s Medium (Cellgro, Hemdon,
VA), supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU/ml
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penicillin, and 100 μg/ml streptomycin. All cell cultures were maintained at 37°C in a 5%
CO2 humidified atmosphere.
Astrocyte cultures were established from 2-5 day old mice. A dissecting
microscope was used to remove the meninges and hippocampus, and the cortices were
mechanically dissociated. Subsequently, cultures were established and maintained in
Dulbecco’s modified Eagle’s medium/Ham's F-12 50/50 mix (Cellgro, Hemdon, VA)
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU/ml penicillin,
100 μg/ml streptomycin and 20 ng/ml epidermal growth factor (Millipore Co., Bedford,
MA) and grown in Primaria flasks, (BD Bioscience, San Jose, CA). After three days of
incubation, cultures were fed with 20 ng/ml epidermal growth factor and the media was
changed after five days. At passage 2 three individual primary cultures of the same
genotype were pooled and seeded for experiments. Only cultures with greater than 80%
astrocyte purity as determined by GFAP immunohistochemistry were included in
experiments.
MTT Assay
Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, MO). In brief, 1000 cells were
seeded per well in 96-well plates. Plates were pre-coated with poly-L-ornithine
(Sigma-Aldrich, St. Louis, MO) and laminin (Invitrogen, Carlsbad, CA) for primary
astrocytes to facilitate cell attachment. Cells were allowed to attach overnight and small
molecules or vehicle control was added to the appropriate wells. After five days, MTT
was added and allowed to incubate for 3 hr. The media was carefully aspirated and the
purple formazan crystals were dissolved in 100 μl DMSO (Fisher Scientific Co., Fair
Lawn, NJ). Absorbance was measured at 570/690 nm using a FLx800 fluorescence
microplate reader (BioTek Instruments, Inc., Burlington, VT). A series of experiments
were conducted to determine the concentration range for each compound to generate a
half-maximal inhibitory concentration (IC50).
Lentiviral Transduction
Luciferase cDNA was amplified by PCR, purified through agarose gel
electrophoresis, and subcloned into BamHI and EcoRI sites of pLenti-pgk-puro vector
(Viral vector core, UTHSC) (Figure 4-1A). The pLenti-Luc-mKate-pgk-puro and
pLenti-pgk-puro lentiviral vectors were packaged in 293T cells [154]. The lentiviral
vectors were used to transduce the U87 glioma cell line in the presence of 6 μg/mL
polybrene (Sigma-Aldrich, St. Louis, MO) (Figure 4-1B). Stably transfected cells were
then selected by growing the cells in 1 μg/ml puromycin. Transduction efficiency was
monitored by using fluorescent microscope.
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Figure 4-1.

pLenti-pgk viral vector.

A, Luciferase and mkate cDNA were subcloned into pLenti-pgk-puro vector using
BamHI and EcoRI sites. B, The lentivial vectors were packaged in 293T cells. The
mock- (U87mock) and Luciferase-transduced (U87Luc) cell lines were generated by
transducing U87 cells with either pLenti-Luc-mkate-pgk-puro or pLenti-pgk-puro
lentivial vector (empty vector), respectively.

62

Luciferase Activity
Luciferase activity was measured in U87 transduced cells using dual-luciferase
reporter assay (Promega, Madison, WI). U87Luc and U87mock were seeded in 6-well plates
and allowed to reach 70% confluency. After removing cell medium and washing once
with PBS, the cells were lysed in 500 μL 1X passive lysis buffer (PLB) for 15 min at
room temperature with gentle shaking. Subsequently, 10 μL of PLB lysate was mixed
with 50 μL LARII (luciferase substrate) and firefly luciferase activity was determined
using GloMax- Multi Jr Single-Tube Multimode Reader (Promega, Madison, WI).
In Vivo Drug Testing
A glioma xenograft mouse model was generated by injecting U87Luc cells
subcutaneously in 4-6 week old NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (Jackson
Laboratory, Bar Harbor, ME. The mice were anesthetized using isoflurane and
subcutaneously injected with 100 μL containing 107 U87Luc cells in the right flank of the
mice. Once the tumors were palpable, the mice were divided randomly into groups of 5
mice (i.e. untreated, vehicle treated, and drug treated). Subsequently, 100 μL of the test
compounds were administered intratumorally. Tumor size, body weight and
bioluminescence signal were obtained twice/week. In addition, non-invasive
bioluminescent imaging was acquired biweekly using the IVIS-200 Imaging System
(Xenogen Corporation, Berkeley, CA). The studies were terminated when the tumors
reached 10% of total body weight.
Statistical Analysis
Mann-Whitney U test was used when only two groups were compared. The
results were considered significant when p < 0.05. All statistical analyses were performed
using Statistica 8 (StatSoft Inc., Tusla, OK).
Results
In Vitro Screening of THIQ Analogs
The anti-cancer activity of THIQ analogs in human glioma cell lines was
investigated in vitro using MTT cell viability assays. In order to determine whether the
compounds had toxicity in normal brain cells, astrocyte cultures were generated from the
cortex of normal mice. Both glioma and astrocytes cultures were plated and treated under
the same conditions. A series of MTT assay were performed to find the dosing range for
each compound to calculate the IC50 values.
TMZ is the standard chemotherapy for treating glioma and was used in the current
study as a reference to evaluate the anti-cancer efficacy of our compounds. T98, U87,
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LN18 and A172 glioma cell lines were more sensitive to TMZ compared to normal
astrocytes (Figure 4-2A). At a concentration 1000 µM, TMZ did not induce 50% death
of normal astrocytes. T98 and LN18 cells were more resistant to TMZ compared to U87
and A172 cells. When glioma cell lines were treated with THIQ compounds, cell death
was induced in a dose dependent manner. EDL-155 was very potent against glioma cell
lines induced ~ 95% cell death at 20 µM (Figure 4-2B). However, it was quite toxic to
normal astrocytes as well (IC50 = 5.2 µM). LN18 was the only cell line that EDL-155
markedly inhibited cell viability at all the concentrations tested and had a significantly
lower IC50 compared to astrocytes (p < 0.05). EDL-323 was significantly more toxic to
LN18 and A172 cells than normal astrocytes (p < 0.05) and completely inhibiting their
viability at 80 µM (Figure 4-2C). Similar to EDL-323, EDL-291 analog significantly
reduced the viability of LN18 and A172 cells (IC50 = 37 and 41.2 µM, respectively)
compared to normal astrocytes (IC50 = 51.1 µM) (p < 0.05) (Figure 4-2D). EDL-355
showed better anti-cancer activity compared to EDL-291 and EDL-323 (Figure 4-2E). It
had significantly lower IC50 value in LN18 cells (IC50 = 7.3 µM) compared to normal
astrocytes (IC50 = 10.3 µM). However, EDL-358 was more selective toxicityto glioma
cell lines (Figure 4-2F). It had a significantly higher IC50 in normal astrocytes compared
to all glioma cell lines (p < 0.05). EDL-360 showed a higher cytotoxic action in glioma
cell lines (IC50 = 5.4- 10,4) µM compared to EDL-358 (IC50 = 8.25- 24.6). In addition, it
significantly induced cell death in all glioma cell lines compared to normal astrocytes (p
< 0.05) (Figure 4-2G). Further modification in EDL-361 resulted in an increased toxicity
in normal astrocytes, and hence a decrease in selective toxicity for glioma cell lines
(Figure 4-2H).
In Vitro Screening of Chromene Analogs
Next, we assessed the anti-glioma toxicity of chromene analogs in vitro. MTT cell
viability assay showed high anti-glioma activity of SP-6-19. Greater than 90% of glioma
cells were dead at a 10 µM concentration, whereas the same dose killed < 50% of normal
astrocyte cells (Figure 4-3A). The observed cytotoxicity in glioma cell lines was in
nanomolar range (IC50 < 80 nM). In contrast, a concentration of 9.5 µM was required to
reach an IC50 in normal astrocytes. It appeared to be most toxic in A172 cell line
compared to LN18 and U87 cells. SP-6-21 was less toxic compared to SP-6-19.
However, the observed cytotoxicity remained in the submicromolar range in glioma cell
lines (Figure 4-3B). All the test glioma cell lines appear to respond equally to the toxic
action of this analog. SP-6-23 exhibited even less toxicity compared to SP-6-21. IC50
values ranged from 0.7-0.9 µM in all glioma cell lines (Figure 4-3C). Approximately,
90% cell death was observed in T98 and U87 cells at 20 μM, whereas, in LN18 and A172
was ~5% at the same concentration. Chromene analog, SP-6-25, exerts anti-glioma
activity in micromolar range (~1.2 μM) (Figure 4-3D). Interestingly, astrocytic cell death
was only observed at the 100 μM concentration. Approximately, a 60-fold higher
concentration is needed to reach IC50 in normal astrocytes. Interestingly, SP-6-27 was the
most potent chromene analog (Figure 4-3E). There was an approximately 90% reduction
of glioma cell viability at 0.1 µM, while in astrocytes the IC50 was ~ 2 µM. All tested
glioma cell lines had a significantly lower IC50 values compared to normal astrocytes (P < 
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Figure 4-2. The effect of THIQ analogs and TMZ on the cell viability of gliomas
and astrocytes.
A, The glioma cell lines were more sensitive to TMZ compared to normal astrocytes. B,
THI analog; EDL-155 was more toxic to both normal astrocytes and human glioma cell
lines compared to TMZ. C, EDL-323 derivative showed less potency against glioma cell
lines when compared to EDL-155. However, LN18 and A172 had a significant less
viabilities and IC50 compared to normal astrocytes. D, EDL-291 analog exhibited a
similar activity profile to EDL-323 in terms of toxicity and selectivity. E, Methoxy
meta-substitution (EDL-355) enhanced the toxicity, however the selectivity remained
poor. F, Methoxy para-substitution (EDL-358) had similar toxicity pattern against glioma
lines compared to EDL-155. More importantly, EDL-358 had a significant higher IC50 in
normal astrocytes compared to for all glioma cell lines. G, Adding one carbon atom to
the carbon linker between biphenyl and THI ring (EDL-360; n = 1) improved both
toxicity and selectivity of EDL-360 analog. H, Further increasing the length of the
carbon linker (EDL-361; n = 2) reduced the toxicity against glioma cell lines when
compared to EDL-360 and showed almost equal potency to normal astrocytes. MTT cell
viability using escalated doses of the test compounds (left panels). Bar graphs comparing
the IC50 data for normal mouse astrocytes and human glioma cell lines (right panels).
Bars represent the means; whiskers represent the standard deviation (±), *p < 0.05.
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Figure 4-3.
astrocytes.

The effect of chromene analogs on the cell viability of glioma and

A, LN18, U87 and A172 had significantly lower IC50 values for SP-6-19 compared to
normal astrocytes. B, SP-6-21 was less toxic compared to SP-6-19. However, the
observed cytotoxicity remained in the submicromolar range in glioma cell lines. C,
SP-6-23 exhibited even less toxicity compared to SP-6-21. D, Chromene analog,
SP-6-25, exerts anti-glioma activity in micromolar range. Interestingly, astrocytes were
quite insensitive to its cytotoxicity. E, SP-6-27 showed an enhanced activity and
selectivity. All tested glioma cell lines had significantly lower IC50 values compared to
normal astrocytes. F, SP-6-35 appeared to be less active compared to SP-6-27 and it
selectively induced cell death in T98 and LN18 compared to U87 and A172. G,
Similarly, SP-6-37 exhibited a selective toxicity in LN18 and A172 compared to T98 and
U87. Up to 100 µM of SP-6-37 did not cause significant cell death in astrocytes. H,
There is a large decrease in SP-6-41 activity compare to any other chromene compound
tested thus far. However, it was not quite toxic to astrocytes compared to glioma cell
lines. I, SP-6-43 showed a slightly higher anti-glioma effect compared to SP-6-41. MTT
cell viability using escalated doses of the test compounds (left panels). Bar graphs
comparing the IC50 data for normal mouse astrocytes and human glioma cell lines (right
panels). Bars represent the means; whiskers represent the standard deviation (±), *p <
0.05. Adapted with permission from Patil R, Hosni-Ahmed A, Jones T, Patil S, Asres L,
et al. (2014) Synthesis and In Vitro Evaluation of Novel 1,2,3,4-Tetrahydroisoquinoline
Derivatives as Potent Antiglioma Agents. Anticancer Agents Med Chem (In Press).
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0.05). In contrast, SP-6-35 had a much lower activity compared to SP-6-27 (Figure
4-3F). SP-6-35 selectively induced cell death in T98 and LN18 cells compared to U87
and A172 cells. The IC50 values ranged from 1-3 µM in glioma cell lines, and it was
approximately 90 µM in normal mouse astrocytes. Similarly, SP-6-37 exhibited selective
toxicity in LN18 and A172 compared to T98 and U87 cells (Figure 4-3G). Up to 100 µM
of SP-6-37 did not cause significant cell death in astrocytes. There is a large decrease in
SP-6-41 and SP-6-43 activity compared to any other chromene compounds tested thus far
(Figure 4-3H and Figure 4-3I). However, it was not as quite toxic in astrocytes as
compared to glioma cell lines. Astrocytes had a higher viability at 1, 5, 10, 50 and 100
µM of SP-6-41 and the IC50 in astrocytes was significantly higher than on glioma cell
lines. Finally, SP-6-43 showed a slightly higher anti-glioma effect compared to SP-6-41.
The IC50 value for glioma cell lines ranged from 6 to 15 µM, whereas in astrocytes it was
> 100 µM.
Effect of EDL-360 in Human Glioma Xenograft Mouse Model
Based on in vitro screening results, EDL-360 was found to be the most potent
THIQ analog. To assess its anti-glioma activity in vivo, mice bearing U87 glioma
xenografts were treated with a daily single dose of EDL-360, and tumor engraftment
examined by caliper and xenogen animal imaging. For bioluminescence imaging, U87
glioma cell line was transduced with the pLenti-Luc-mKate-pgk-puro viral vector, and
the cells were grown in puromycin to select stably transfected cells. Luciferase activity
was measured in U87luc and U87mock cultures using dual-luciferase reporter assay. Mean
luciferase luminescence was 1.79 X107/8.3 X 105 cells (± 6.4X105) and 173/7.8 X 105
cells (± 19) relative light units (RLU) in U87luc and U87mock, respectively. To generate the
glioma mouse model, U87luc cells were injected subcutaneously into the right flank of 4-6
week old BALBc (NSG) mice. Once the tumor became palpable the mice were randomly
assigned into groups of 5 mice. The treated group received 5 μM of EDL-360 daily,
whereas the control group did not receive any treatment. Mice were monitored daily for
any signs or symptoms of drug related toxicity. In addition, mice were weighed twice a
week. There was no sign of toxicity or weight loss in the EDL-360 treated group
compared to the control mice (Figure 4-4A).
Tumor dimensions (width, length and height) were obtained using a digital caliper
to determine tumor volume (mm3). Tumor volume of each mouse was normalized to the
initial volume before starting EDL-360 treatment (day 0). A slight attenuation of tumor
growth was observed as early as 3 days post-treatment (P = 0.077) (Figure 4-4B). The
tumors in the EDL-360 treated mice were significantly smaller compared to control mice
after 7, 10 and 14 days of treatment (P = 0.03, 0.02, and 0.02 respectively). The
difference in tumor size between EDL-360 treated tumors and the controls increased with
time of treatment. For instance, 3 days after treatment the EDL-360 treated tumors were
1/3 the size of the control group (Mean =1.5 vs 5 normalized tumor volume). After 14
days of treatment, the treated tumors were 1/6 the size of control group (Mean = 12.5 vs
74 normalized tumor volume). In addition, non-invasive live imaging was employed to
evaluate tumor growth in EDL-360 and control mice. Bioluminescence signal showed an
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Figure 4-4. Intratumoral treatment with EDL-360 in human glioma xenograft
mouse model.
U87luc cells were injected SQ into the right flank of the mice. Once the tumor become
palpable the mice were randomly placed in the study. A, Mouse weight was obtained
twice a week. There was no sign of toxicity or weight loss in EDL-360 treated group
compared to the control mice. B, Tumor dimensions (width, length and height) were
obtained using digital caliper to determine tumor volume. The tumors of the control mice
were growing significantly faster compared to EDL-360 treated mice (P < 0.03). C,
Bioluminescence signal from control and treated mice showed an obvious decrease in
tumor viable cells after 17 days of treatment. D, Quantification of bioluminescence
signals showed a continuous tumor growth in the control mice. In addition, there was a
significant decrease in tumor growth in the drug treated mice compared to the controls (P
< 0.03). Bars represent the means; whiskers represent the standard deviation (±); * p <
0.05.
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obvious decrease in tumor viable cells at 17 days of treatment compared to the controls
(Figure 4-4C). Quantification of photons showed a continuous tumor growth in the
control mice (Figure 4-4D). In addition, EDL-360 treated tumors had a significantly
lower growth rate compared to the controls (P < 0.03).
Effect of SP-6-27 in Human Glioma Xenograft Mouse Model
SP-6-27 was the most potent chromene analog in glioma cell lines in vitro and its
activity was assessed in U87luc human glioma xenograft mouse model. Glioma-bearing
mice were randomly divided into 3 groups. Treated groups received 100 μL daily dose of
0.2 or 2 μM SP-6-27/0.1% acetic acid, whereas the control group received 100 μL of
0.1% acetic acid. Mice were monitored daily for any signs or symptoms of drug related
toxicity. Total body weight, tumor volume, and bioluminescence imaging were obtained
twice a week during the study period. However, it appeared that the low pH environment
created by the use of acetic acid affected the bioluminescence signal [172]. Therefore, the
bioluminescence imaging results were excluded from the study. We observed no signs of
drug related toxicity in the treated groups. In addition, there was no weight loss in
SP-6-27 or vehicle treated groups (Figure 4-5). Drug treated groups had a smaller tumor
volume compared to the vehicle treated group. Mice receiving 2 μM SP-6-27 had
significantly smaller tumors after 4 and 11 days of treatment (p = 0.016). As expected,
tumor size decreased in a dose dependent manner.
Discussion
The THIQ analog, EDL-155, was found to be the most potent analog in rat
glioma model [165]. When compared to other anti-cancer agents such as 5-fluorouracil,
BCNU and melphalan, EDL-155 most effectively induced glioma cell death. In
agreement with previous studies, EDL-155 was found to be very potent. The IC50 values
ranged from 6-15 µM depending on the glioma cell line [165]. In the current study, we
showed that all the THIQ analogs tested were more potent than TMZ, a standard
chemotherapeutic agents for treating glioma. Interestingly, LN18 cells were resistant to
the cytotoxic action of TMZ (~390 µM) and in our study EDL-155 was found to be
highly toxic to LN18 cultures (~ 4 µM) (Figure 4-2B). This could indicate a potential use
of our THIQ derivatives in combination with TMZ for TMZ-resistant gliomas. Further
modifications in the A and D rings were made in attempt to improve the toxicity as well
as the selectivity. The activity was lost in EDL-232 and partially recovered by adding 2
ortho-methoxy groups in A ring. Consequently, structure activity relationship showed
that changing the methoxy groups to meta- (EDL-355) and para-position (EDL-358)
(Figure 4-2E and Figure 4-2F), resulted in an obvious improvement of the cytotoxicity
(EDL-355) as well as selectivity (EDL-358). Additionally, we lengthened the carbon
linker between biphenyl and THI ring to 2-carbon atoms (EDL-360), which resulted in a
further increase in the potency of the compound while maintaining low toxicity in
astrocytes. However, adding an additional carbon atom (EDL-361) led to decreased in
the cytotoxicity (Figure 4-2H). In conclusion, in vitro screening suggested that EDL-360
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Figure 4-5. Intratumoral treatment with SP-6-27 in human glioma xenograft
mouse model.
The mice were divided in 3 groups, 5 mice/group. Control mice were injected daily with
0.1% acetic acid and treated groups were injected daily with 0.2 μM or 2 μM SP-6-27 in
0.1% acetic acid. A, Mice weight was obtained twice a week. There was no sign of
toxicity or weight loss in SP-6-27 treated group compared to the vehicle control mice. B,
Tumor dimensions (width, length and height) were obtained using digital caliper to
determine tumor volume. Tumors in the SP-6-27 treated groups were growing at a slower
rate compared to the control mice. Mice that received 2 μM SP-6-27 had significantly
smaller tumors after 4 and 11 days of treatment (p = 0.016). Bars represent the means;
whiskers represent the standard deviation (±); * p < 0.05.
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is the most potent THIQ analog. Interestingly, it appears that EDL-360 exhibited a
selective toxicity in LN18 and A172 cultures when compared to T98 and U87 cultures
raising the potential of use of this analog in the clinical setting for gliomas that are
resistant to TMZ.
Chromene analogs were a second group of compounds that were assessed for their
potency against glioma. Chromenes are analogs of podophyllotoxin, a natural plant
product, that have been isolated from Podophyllum species [169]. Early clinical trials
revealed that podophyllotoxins induce cell death by inhibiting microtubule assembly
[169]. In addition podophyllotoxins can inhibit purine biosynthesis and its incorporation
into the RNA as well as decreasing the activity of mitochondrial enzymes such as
cytochrome oxidase and succinoxidase. More importantly, podophyllotoxin derivatives
are potent inhibitors of DNA topoisomerase II and hence induce cell death [173].
Consequently, several studies reported these derivatives as potent anti-cancer agents
[174-177]. In vitro screening of various chromene analogs revealed that SP-6-25,
SP-6-35, SP-6-41 and SP-6-43 are the least potent analogs (Figure 4-3). The IC50 of
these compounds was in micromolar range. However, SP-6-27 followed by SP-6-19 were
the most potent chromene analogs tested in the current study. More importantly, these
compounds demonstrated very low activity in normal astrocytes compared to glioma cell
lines, implying a potential benefit with least toxicity. Based on structure activity
relationship, it appears that the substitution of electron withdrawal atom on D-ring and/or
electron donor atom on C-ring resulted in an improvement of chromene potency [168].
Based on our in vitro drug screening findings, we selected the most potent THIQ
(EDL-360) and chromene (SP-6-27) analogs for in vivo evaluation in human glioma
xenograft model to address this question. EDL-360 caused partial regression in tumor
size (Figure 4-4B) without causing a notable toxicity in the treated mice (Figure 4-4A).
Tumor size was determined by digital caliper measurement and live animal
bioluminescence imaging (Figure 4-4C and Figure 4-4D). However, it is still unclear
whether EDL-360 could penetrate the BBB, and would exert a similar anti-cancer effect
when the tumors were grown intracranially. Previous studies showed that EDL-155 could
penetrate the BBB, with 1.4% brain to plasma exposure ratio [178]. However, it is not
possible to expect that EDL-360 would exhibit good penetrance across the BBB as well.
Slight variation in the chemical structure could lead to great changes in the biological
responses. Similarly, tumor-bearing mice that were treated with SP-6-27 did not lose
weight or showed signs of toxicity (Figure 4-5A). Additionally, SP-6-27 treatment
caused a partial regression in tumor size (Figure 4-5B) similar to EDL-360 treated
tumors. However, treatment with the vehicle (acetic acid) resulted in in a slight decrease
in tumor growth, which in part could mask the effect of SP-6-27. In conclusion,
EDL-360 and SP-6-27 have potential as anti-cancer agents. However, the limited
solubility of SP-6-27 in aqueous solutions may be a limiting factor. Further investigations
are required to test the anti-cancer activity of these small molecules in pre-clinical glioma
mouse models.
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CHAPTER 5.

DISCUSSION AND CONCLUDING REMARKS

Over the past 10 years, despite improvement in diagnosis and therapies for cancer,
the survival rate for high-grade glioma patients remains low. In the current study, we
investigated the effects of corticosteroids and thiopurines in the brain because they have
been associated with increased resistance to chemotherapy or gliomagenesis,
respectively.
Corticosteroids Might Reduce the Efficacy of Chemotherapy and Radiotherapy
Vasogenic edema develops in aggressive gliomas and corticosteroids are the first
clinician choice to alleviate the neurological symptoms [9,72]. Despite the intensive use
of Dex in the clinic, its effect on glioma is not precisely identified. Whether Dex has
anti-proliferative or anti-neoplastic properties, or whether it stimulates cell growth has
been a long debate in the literature [35,36,76,77]. We have found that Dex treatment
decreases tumor cell proliferation as shown by PCNA and Ki67 IHC staining and hence it
exhibits an anti-proliferative effect. Since cancer therapeutics often target rapidly
growing cells, it is quite possible that Dex might compromise the responsiveness of
tumor cells to chemotherapy and/or radiotherapy via inhibiting tumor cell growth.
Indeed, several studies suggested that Dex might compromise the responsiveness of
tumor cells to chemotherapy and/or radiotherapy[37,92,93]. Pre-treatment with Dex
induces Bcl-xL expression and inhibited cell death induced by staurosporine,
camptothecin and etoposide in astrocytoma cultures [93]. In breast and ovarian xenograft
animal model, pretreatment with 1 mg/kg of Dexwas found to reduce the anti-cancer
action of paclitaxel by 20-25% [179]. Such findings highlight the desperate need to
understand the exact effect of Dex on tumor cells especially for patients undergoing
chemotherapy or radiotherapy concurrently with corticosteroids, and raises the concern
that Dex treatment should not be combined with DNA damaging agents such as
chemo- and radio-therapy.
Corticosteroids Decrease Microglial Cell Number and M2-Like Microglial Cells
The mechanism of how Dex alleviates cerebral edema is mostly unknown.
However, it has been proposed that Dex might improve peritumoral edema through its
anti-inflammatory effect or by inhibiting microglial cells proliferation and
pro-inflammatory cytokine production [68,73]. In rat glioma, DEX was found to decrease
microglial cell proliferations infiltration into the tumor [73]. In the current study, we
found that Dex decreases microglial cell content in tumor sections as confirmed by
anti-Iba-1 primary antibody in PDGF driven glioma mouse model. (Figure 2-6A).
However, two different phenotypes of microglial cells exists; M1 and M2. M1-like
microglial cells are known to possess pro-inflammatory properties. In contrast, various
studies suggested that tumor-associated microglia could support the tumor proliferation
and growth, and possess an M2-like anti-inflammatory phenotype [78,97,98]. In

84

agreement with previous findings, we found that tumor associated microglia exhibit an
M2-phenotype in a PDGF induced-glioma model (Figure 2-7). This implies that
inflammatory microglial cells may not play a major role in edema formation, and Dex
might alleviate peritumoral edema by a mechanism other than inhibiting the
M1-pro-inflammatory microglial cells.
Several studies found a decrease in the production of several pro-inflammatory
cytokines such as COX2, NO, IFNγ and TNFα in lipopolysaccharide induced upon Dex
treatment [180-182]. However, lipopolysaccharide induces the classical activation of
microglial cells to M1-pro-inflammatory phenotype and it is well defined that microglial
cell exhibit M2-pro-tumor phenotype in tumor microenvironment [78,86]. To our
knowledge, this is the first study that investigates the effect of Dex on the gene
expression of M2-like microglial cells using a clinically relevant glioma model. We
found a shift in the microglia phenotype towards less M2 (MMP9 and IL-1ra) in both in
vitro and in vivo samples upon Dex treatment. MMP9 is a member of matrix
metalloproteinases family, which is produced primarily by immune cells such as
macrophages/microglias and neutrophils [101]. MMP9 plays a pivotal role in tumor
progression and invasion [97]. MMP9 deficient mice have less lung metastases in both
melanoma and lung carcinoma animal models [102]. More importantly, MMP9 plays an
important role in angiogenesis and induction of cell proliferation [101,103,104]. It is
plausible that targeting M2-microglial cells could have a potential therapeutic benefit for
treating glioma [183]. However, the use of corticosteroids in managing glioma is
problematic, since it is associated with a decreased response to anti-cancer therapy.
Consequently, we addressed the question of whether this decrease in M2-pro-tumor
phenotype could play a role in tumor cell proliferation in Dex treated samples. Therefore,
we investigated the anti-proliferative effect of Dex using primary glioma cultures. In
contrast to our in vivo results, we could not detect a cell proliferation inhibition following
Dex treatment. These contradicting findings highlight the difference between in vitro and
in vivo conditions and this does not eliminate the possibility that microglial cell play an
important role in supporting tumor cell proliferation.
Taken together, Dex might act against glioma favorable conditions in our mouse
model. However, this effect might or might not be recapitulated when Dex is combined
with DNA damaging agents such as ionizing radiation. Finally, the current study
highlights the urgent need to find better therapeutic alternatives to corticosteroids that
have less adverse effects and interfere less with anti-cancer therapy. Further studies
should focus on identifying the mechanism of action by which Dex inhibits cell
proliferation. In addition it is important to investigate whether Dex alleviates preitumoral
edema by inhibiting the expression of VEGF and hence decreases the permeability of the
BBB.
Low TPMT Activity Leads to Increases in TG-Induced Toxicity
Thiopurine drugs are commonly used in the treatment of cancer, autoimmune
disorders, and transplantation. TPMT is a cytoplasmic enzyme that deactivates thiopurine
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drugs and a low TPMT phenotype can lead to life-threatening hematological toxicities
when standard doses of thiopurines are given. The use of these agents has been linked
with the development of secondary brain tumors in TPMT-deficient patients [42,47].
Astrocytomas are the most common brain tumor type that has been reported in patients
after thiopurine therapy [47,48,50,67]. Unfortunately, not all patient populations that are
treated with thiopurines are evaluated for their TPMT status prior to initiating thiopurine
therapy; hence, the importance of TPMT to thiopurine-associated cancer risk is not clear.
Since TPMT deficiency is relatively rare across populations, it is difficult to assess the
importance of TPMT status to thiopurine therapy-related cancer risk. However, in a
report by Relling et al. it was shown that whether patients developed a brain tumor as a
late complication of post-antileukemic therapy depended on their TPMT status [47].
Patients who were determined to be at high risk for treatment relapse received
prophylactic cranial irradiation concurrent with antimetabolite therapy; and those patients
with a low TPMT had a surprisingly high incidence of brain tumors as a late
complication. Indeed, ionizing radiation is a risk factor for brain tumorigenesis. However,
in this report, patients with low TPMT had a 42.9% incidence of brain tumors compared
to 15.8% for those with high TPMT. To our knowledge, the importance of TPMT status
to thiopurine-associated phenotypes in the brain has not been investigated.
We found that low TPMT phenotype was associated with significantly higher
sensitivity to thiopurine than a high TPMT phenotype. In agreement with previous
studies, we found that thiopurines induced significantly more cell death and DNA
damage (SSB and DSB) [156]. Interestingly, we found that low but not the complete
absence of TPMT sensitized primary astrocytes to a higher degree of cytotoxicity and
genotoxicity (i.e. IC50, SSBs and DSBs) after TG exposure. These results suggested that
heterozygosity in TPMT may lead to the greatest genotoxic effects of thiopurine therapy.
In part this could be explained by the induction of compensatory mechanism that
deactivates thiopurines upon the complete loss of TPMT. The loss of TPMT could have
led to the overexpression of xanthine oxidase, which deactivates thiopurine agents to
thiouric acid. Interestingly, some studies suggest that children with TPMT heterozygosity
develop brain tumors and other cancers more frequently than children with mutant TPMT
[164]. Another possible explanation could be a defect in the mismatch repair (MMR)
system's ability to recognize DNA-TG nucleotide lesions in TPMT mutant cultures. The
MMR system is responsible for recognizing DNA mis-pairing caused by DNA-TG
nucleotides and the subsequent signaling for cell death [160-163]. The latter possibility
suggests that astroglial cells with a defective TPMT activity could have DNA lesions
persisting in the genome that could potentially lead to mutagenesis and cancer. However,
the frequency of heterozygous or mutant TPMT is very low making it is difficult to make
any definitive conclusions [47,164]. Indeed the current study raises the concern about
thiopurine toxicity not only in TPMT mutant individuals but also in TPMT heterozygous.
Therefore, a routine assessment of TPMT activity might be required for patients
receiving thiopurine agents.
In summary, chronic thiopurine therapy has been associated with the development
of brain cancer and TPMT status has been linked to brain tumor risk. We found that
TPMT is an important factor for thiopurine drug-induced cytotoxicity and genotoxicity in
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astroglial cells. Because of the limited availability of human astrocytes we used human
glioma cell lines. Although glioma cells can exhibit a number of genetic alternations that
could contribute to the phenotypes observed, our study shows that TPMT is indeed an
important determinant of thiopurine toxicity. The observation that glioma cells can have
variable degrees of TPMT protein activity and that low protein activity can cause cells to
be more sensitive to TG may suggest that thiopurines may potentially have a therapeutic
role in low TPMT expressing glial tumors. However, since thiopurine drugs are linked
with secondary brain tumors, we do not recommend the use of these agents in brain
tumor treatment. Furthermore, In vitro studies have shown that thiopurine drugs are
associated with mutagenic events in a variety of cell lines [116,151].
Further studies are needed to understand the importance of TPMT in the brain
when thiopurines are given. Whether these findings can be replicated in vivo and whether
factors important to DNA repair mechanisms are responsible for the TG phenotypes
described in this study should also be investigated. Finally, It would be interesting to
investigate whether TPMT status influences the extent of TG nucleotide incorporation
into DNA and damage recognition by the MMR system as well as whether ionizing
irradiation alone or in combination with thiopurines results in similar findings.
EDL-360 and SP-6-27 Exhibit Anti-Glioma Activity In Vitro and In Vivo
Despite aggressive therapeutic approaches to treat glioma, there is no significant
improvement in either the prognosis or the survival of patients. Therefore, there is an
urgent need to find new therapeutic approaches to improve patients’ survival and
outcome. The current study focused on assessing the potential anti-cancer activity of two
categories of small molecules; THIQ and chromenes.
The anti-cancer activity of our compounds has been tested in vitro using MTT cell
viability assays. Since glioma is a heterogeneous tumor, the in vitro drug screening was
performed in four human glioma cell lines (T98, U87, LN18 and A172). Although
normal human astrocyte cultures may be more appropriate as a model of normal brain
cells, normal murine astrocyte cultures were used due to their availability in our
laboratory. Based on our in vitro screening, we identified EDL-360 and SP-6-27 as the
most potent derivatives with lowest toxicity to normal stromal cells. Interestingly, it
appears that EDL-360 exhibited a selective toxicity in LN18 and A172 cells when
compared to T98 and U87 cells raising the potential use of this analog in the clinical
setting for gliomas that are resistant to TMZ. SP-6-27 exhibits cytotoxicity in nanomolar
range (IC50 = 7-21 nM). Tubulin polymerization inhibition could in part play a role in
SP-6-27 induced toxicity [168]. However, inhibition of tubulin polymerization by
SP-6-27 was weak and other mechanism of actions might play a major role in SP-6-27
induced toxicity.
The anti-cancer activity of EDL-360 or SP-6-27 was further tested in
glioma-bearing mice generated by injecting human glioma U87luc cells subcutaneously in
immunocompromised mice. Despite the fact that U87 cell produces glioma characterized

87

by leaky BBB similar to human glioma, the tumor does not have infiltrative nature [19].
There was no sign of toxicity as indicated by the absence of weight loss in the treated
groups (EDL-360 and SP-6-27) compared to the control mice. The tumors of EDL-360
treated mice were significantly smaller compared to control mice after. In contrast
SP-6-27 treatment resulted in a partial regression of tumor size. However, it is still
unclear whether EDL-360 or SP-6-27 could penetrate the BBB and exerts a similar
toxicity when the tumors grown intracranially. Previous studies showed that EDL-155
(THIQ analog) could penetrate the BBB, with 1.4% brain to plasma exposure ratio [178].
However, it is possible to expect that EDL-360 would exhibit better penetration of the
BBB since it is a methoxy rather that a penolic substituted compound. Slight variation in
the chemical structure could lead to great changes in the biological responses. Similarly,
SP-6-27 treatment caused a partial regression in tumor size. However, acetic acid treated
tumors did not grow as fast as non-treated tumors and this in part masking the effect of
SP-6-27. It is also plausible that the stromal cells provide growth support to the tumor
cells, rendering SP-6-27 ineffective.
In conclusion, EDL-360 and SP-6-27 have potential as anti-cancer agents.
However, the limited solubility of SP-6-27 in aqueous solutions could be a limiting factor
for its use. The synthesis of the corresponding sodium or phosphate salts of SP-6-27 may
enhance its water solubility. Probing the structure activity relationship of EDL-360 may
improve its anti-cancer activity. In addition, further investigations are required to test the
anti-cancer activity of these small molecules in an intracranial xenograft model, which
would allow tumor development in the native microenvironment of the brain, and thus
allows more reliable assessment of anti-glioma novel therapies.
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